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ABSTRACT  
Rab and Rho subfamilies of GTPases are functionally linked to intracellular trafficking 
and organization of the cytoskeleton respectively. Despite their roles, use of small 
molecule inhibitors or activators to map the functionality of these GTPases remains 
largely underexplored due to lack of suitable compounds. In this dissertation, we report 
on the functional characterization of Rab7 and Rac1 GTPases using small molecules. 2-
(benzoylcarbamothioylamino)-5,5-dimethyl-4,7- dihydrothieno[2,3-c]pyran-3-carboxylic 
acid (PubChem #: CID1067700)  has been used to characterize Rab7.  Using bead based 
flow cytometry, CID1067700 was found to have significant inhibitory potency on Rab7 
nucleotide binding with a respective inhibitory efficacy of 80% for BODIPY-GTP and 
	   viii	  
60% for BODIPY-GDP binding. Rac1 has been functionally characterized by non-
steroidal anti-inflammatory drug (NSAID), R-Naproxen in the context of ovarian cancer. 
R-Naproxen isoform functionally inhibited Rac1 in the cell lines assayed relative to S-
Naproxen and structurally similar 6-methoxy-2-naphthylacetic Acid (6-MNA). Inhibition 
is based on interference with membrane distribution of Rac1 rather than overall protein 
levels. Taken together, this study has identified the first competitive GTPase inhibitor 
(CID1067700) and also demonstrated the potential utility of the compound for dissecting 
GTPase enzymology. The study has also shown that R-Naproxen blocks activation of 
Rac1 small GTPase in ovarian cancer cells with implications for the inhibition of ovarian 
cancer cell proliferation, migration, and invasion. 
Key Words: Rab, Rho, Rac, Cdc42 and Ras GTPases; drug discovery; fluorescent GTP 
and GDP; enzyme kinetics; GEF; flow cytometry, ovarian cancer, competitive and 
allosteric inhibitors. 	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CHAPTER ONE 
 INTRODUCTION 
Overall introduction: Ras superfamily of GTPases 
    Small GTPases (Ras superfamily) are intracellular, molecular switches that activate 
downstream signaling molecules in response to extracellular and intracellular cues. There 
are five families: Ras, Rho, Arf/Sar1, Rab, and Ran.  Biochemical studies have revealed 
many commonalities between small GTPases with respect to synthesis, post-translational 
modification, activation, inactivation, and transmission of signals to downstream effector 
molecules. Characteristically, small GTPases switch between inactive [guanosine 
diphosphate (GDP) bound] and active [guanosine triphosphate (GTP) bound] 
conformational states (Fig. 1) (1-4). The conformational switch involves specific 
regulatory proteins. While guanine nucleotide exchange factors (GEFs) catalyze release 
of bound GDP to allow for GTP binding by small GTPases (5), GTPase activating 
proteins (GAPs) on the other hand, facilitate hydrolysis of GTP on the membrane bound 
small GTPase proteins. 
    Conversion between GTP- and GDP-bound states is also associated with transitions 
between membrane and cytosolic compartments, respectively (Fig. 1). Translocation of 
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the small GTPase to the cytosolic compartment is facilitated by guanine dissociation 
inhibitors (GDI-1 or GDI-2), while membrane association is facilitated by Rab escort 
protein (REP) immediately after synthesis and prenylation or by GDI during membrane 
recycling (Fig. 1) (6). Upon activation, the GTP-bound, membrane associated small 
GTPases bind to and transmit signals to multiple effector molecules. Besides regulating 
vital cellular processes such as cell signaling, members of Ras superfamily of GTPases 
via interdigitated functions of Ras, Rho, Arf/Sar1, Rab, and Ran individual subfamily 
members, regulate intracellular trafficking, nuclear translocation and cytoskeletal 
rearrangements that occur in response to extracellular signals and cellular needs. 
Together the GTPase regulated cascades enable metabolic homeostasis, cell migration, 
cell growth and division, cell differentiation and polarization.  
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Figure 1. Principal processes governing the regulation of small GTPases. Newly 
synthesized small GTPases are modified on C-terminal cysteine residues by lipid 
moieties (prenyl or farnesyl chains) to ensure membrane recruitment via REP. GEFs and 
GAPs act as small GTPase signal activators and attenuators, respectively. GDI serves to 
regulate membrane-cytosol cycling.   
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    The involvement of small GTPases in diverse human diseases presents the small 
GTPases as novel targets for therapeutic intervention hitherto not extensively explored. 
Diverse points of small molecule modulation of small GTPase function are possible 
ranging from prenylation inhibition to protein-protein interaction regulation (Fig. 1). A 
precedent already exists with respect to the use of small molecule inhibitors to prevent 
small GTPase membrane recruitment, through inhibition of protein prenylation or 
inhibition of regulatory protein interactions (7, 8). Because of the broad cellular 
importance of lipid modifications for protein function, the former approach has not 
however yielded the selectivity necessary for many applications, though the identification 
of more specific prenylation inhibitors remains under active investigation (9-12).  
    The inhibition of regulatory protein interactions on the other hand holds promise for 
being more specific, with the best-characterized example provided by brefeldin A 
mediated inhibition of Arf GEF activity (13). Within the Rho-family GEFs, a few 
successful attempts have been made to identify inhibitors through screening and rationale 
drug design (13-16). It is important to point out that these successes have not been 
replicated in any of the members of the Rab family of GTPases whether in terms of 
nucleotide binding inhibitors or modulators of protein-protein interactions, in spite of 
their cellular importance in cancer and genetic diseases (17, 18).  
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    Different strategies can be applied to realize the therapeutic potential of small 
GTPases. One strategy is to target the central regulatory properties of small GTPases 
based on the switch between GDP and GTP bound states, by finding a small molecule 
that can modulate nucleotide binding by the small GTPase.  A second strategy is to 
identify small molecules that inhibit protein-protein interactions required for GTPase 
function. The use of a small molecules is also important to characterize protein function 
and has advantages to traditional approaches that rely on dominant negative mutants. 
These include, but are not limited to; fast and often-reversible inhibition of protein 
function, informative dose–response data, providing room for studying protein of interest 
in a multimeric complex without the latter falling apart and availability of small molecule 
compounds. All these advantages collectively can lead to a novel endpoint and that is, 
providing new insights into mechanistic details of GTPase functions in cellular processes. 
In this study, we have sought to assay how small GTPases can be functionally modulated 
by small molecules in vitro as well as in a cellular context. 
Hypothesis of the dissertation study 
   Small GTPases are functional targets of small molecules that act as competitive or 
allosteric inhibitors. 
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Aims of the study  
   The central goal of the study was to identify and characterize small molecule inhibitors 
of Ras-related GTPases. The stated hypothesis is addressed through two specific aims. 
Aim 1 utilizes an in vitro, flow cytometry based assay to distinguish the mechanism of 
small molecule action on the Rab7 GTPase.  Aim 2 utilizes in vitro and cell based assays 
to characterize functional inhibition of the Rac1 GTPase.  
Aim1: Mechanism of small molecule Rab7 GTPase inhibition. 
   The first aim of the study was designed to characterize the mechanism of inhibition of 
Rab7 by a sulphur based small molecule; 2-(benzoylcarbamothioylamino)-5,5-dimethyl-
4,7- dihydrothieno[2,3-c]pyran-3-carboxylic acid (CID 1067700; PubChem 
CID1067700). CID1067700 was identified at the University of New Mexico Center for 
Molecular Discovery (UNMCMD) by screening the NIH Roadmap library of over 
300,000 compounds (Pubchem AID 1333, 1334, 1340). To address the first aim, a bead 
based flow cytometry approach was used (Fig. 2), where gluthione-S-transferase (GST) 
tagged Rab7 was mobilized on a glutathione bead and then the effect of CID1067700 
assayed in terms of loss of BODIPY-GTP or -GDP binding by Rab7.  The approach 
enables distinction of allosteric or competitive inhibition of nucleotide binding (Fig. 2). 
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Using the bead based approach; the effect of CID1067700 on Rab7 was assayed in dose 
dependent binding assays and kinetic measurements of nucleotide binding and 
dissociation.  Structure activity relationships of several chemical analogs of CID1067700 
were also tested to establish essential features for small molecule inhibition. 
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Figure 2: Design of glutathione bead based high throughput screening (HTS) to 
identify small GTPase activators and inhibitors. GST-tagged small GTPase is 
immobilized on a gluthathione bead of definite mean diameter (13 µm). The effect of the 
small molecule on the fluorescent nucleotide binding by the GTPase is then assayed 
using flow cytometry. Competitive inhibitor binds the same site as the nucleotide while 
allosteric modulator (activator or inhibitor) binds the indicated site (typically GTPase 
switch region) outside the nucleotide binding pocket. The read out of the assay is mean 
channel fluorescence. 
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Aim 2: In vitro and cell based assays to study functional inhibition of Rac1 GTPase 
   The second aim was centered on the small molecule inhibition of the Rac1 GTPase. 
Functional modulation of Rac1 small GTPase by the non-steroidal anti-inflammatory 
drug (NSAID), R-Naproxen was assessed in the context of ovarian cancer cells. R-
Naproxen was identified the University of New Mexico Center for Molecular Discovery 
(UNMCMD) by screening a Prestwick chemical library of off-patent molecules. The 
effects of R-Naproxen on Rac1 activation status, Tiam1 GEF interaction, membrane 
distribution and overall Rac1 protein levels were measured.   
Biological and chemical connection between Rab7 and Rac1  
   In terms of function, the Rab5, Rab7 and Rac1 GTPases are intimately linked to enable 
coordination between molecular trafficking and actin cytoskeletal remodeling, 
respectively (Fig. 3). It has been shown that Rac1 interaction with endosomes is 
dependent on Rab5 GTPase and that the Rab5-Rac1 circuitry is significant in the role of 
Rac1 in modulating cell motility (19, 20).  This is supported by evidence showing that, 
ectopic expression of Rab5 in HeLa cells increases early endosomal accumulation of 
active Rac1 and Tiam1 GEF as well as induction both lamellipodia and circular dorsal 
ruffles (19). Since Rab5-Rab7 conversion is an important regulatory process in cargo 
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trafficking as will be explained later, one can speculate that it may also be involved in 
Rab5 mediated Rac1 trafficking. Also, Armus which is a Rac1 effector (21, 22), is 
reported to inactivate Rab7 by facilitating nucleotide hydrolysis again suggesting a cross 
talk between Rab7 and Rac1 in trafficking and regulation of actin assembly. The 
composite data emphasize that the cellular role of Rac1 cannot be divorced from the 
endocytic trafficking pathway. We can also emphasize a common denominator with 
respect to chemical connection between Rab7 and Rac1. The current study is about 
CID1067700 and R-Naproxen small molecules capable of functionally impacting Rab7 
and Rac1 respectively.  CID1067700 which competitively inhibits nucleotide binding by 
Rab7, may also inhibit Rac1 by binding the nucleotide binding site since among the Ras 
family of GTPases, the principal amino acid residues of the nucleotide binding site are 
evolutionarily conserved. The potency of inhibition may however vary due to differences 
in the orientation of the nucleotide pocket between the two GTPases. R-Naproxen in this 
study displays characteristics typical of allosteric inhibitor. Thus, its ability to inhibit 
Rac1 may not be replicated in Rab7 due to differences in amino acid residues on its 
binding site between the two GTPases and also the ensuing potential differences in the 
protein conformation which may be caused by its binding. Thus, within the broader 
context of biological and chemical connection, both Rab7 and Rac1 are functionally 
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interdependent and may be modulated in a similar way by a small molecule that displays 
competitive characteristics.  
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Figure 3: Roles of Rab7 and Rac1 small GTPases in molecular trafficking and actin 
remodeling. GDP bound Rac1 is localized at early endosomal membranes where it 
interacts with Tiam1 GEF, converting the protein to the active GTP bound state. Active 
Rac1 interacts with PAK1 effector at the plasma membrane and induces actin 
remodeling.  Rab7 is transiently localized to early endosomes where it facilitates Rab5-
Rab7 conversion and transport of cargo to late endosomes.  Rab7 is important in the 
regulation of antigen processing, growth factor sequestration and lysosomal degradation, 
among other functions. 
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CHAPTER TWO 
CHARACTERIZATION OF RAB7 SMALL GTPASE WITH CID1067700 
Abstract 
   Rab7 plays a significant role in late endocytic events of mammalian cells that serve to 
regulate growth factor downregulation, pathogen degradation, autophagy, among other 
events central to normal cell physiology. Here we report on the small chemical molecule 
2-(benzoylcarbamothioylamino)-5,5-dimethyl-4,7- dihydrothieno[2,3-c]pyran-3-
carboxylic acid (CID 1067700; PubChem CID1067700) as an inhibitor of nucleotide 
binding by Rab7 and possibly other Ras-related GTPases. The mechanism of action of 
this pan-GTPase inhibitor has been characterized in the context of the Rab7 GTPase as 
there are no known inhibitors of Rab GTPases. Bead-based flow cytometry was used to 
establish that CID1067700 had significant inhibitory potency on Rab7 nucleotide binding 
with a respective inhibitory efficacy of 80% for BODIPY-GTP and 60% for BODIPY-
GDP binding.  The compound behaves like a competitive inhibitor of Rab7 nucleotide 
binding based on both equilibrium binding and kinetic assays. Molecular docking 
analyses are compatible with CID1067700 fitting into the nucleotide binding pocket of 
the GTP-conformer of Rab7.  Structural features pertinent to CID1067700 inhibitory 
activity have been identified through an initial structure activity analyses. These studies 
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identified a molecular scaffold that may serve in the generation of more selective probes 
for Rab7 and other GTPases. Using effector protein interaction, we have also shown that 
when CID1067700 is bound to the nucleotide binding site, Rab7 does not adapt 
conformational state analogous to GTP bound  (active) state. Taken together, this study 
has identified the first competitive GTPase inhibitor and demonstrated the potential 
utility of the compound for dissecting the enzymology of the Rab7 GTPase as well as 
serving as a model for other small molecular weight GTPase inhibitors. 
Introduction  
   The founding Rab GTPase family members were identified in secretion deficient yeast 
mutants and in mammalian brain, thereby revealing their essential roles in the regulation 
of membrane trafficking (23-25).  The human genome encodes more than 70 Rab 
GTPases and Rab-like proteins (26-28).  Still only a fraction of these Rab GTPases have 
been studied in significant detail. Currently there are ~25 Rab GTPases with 
characterized functions in endoctyosis and related processes (Appendix A) and (29).  
Rab7 is one of the most studied endocytic Rab GTPases due to its pivotal roles in 
shunting molecules for recycling through the Golgi, back to the plasma membrane or to 
degradation (Fig. 4).   
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Figure 4: Intracellular trafficking pathways associated with Rab7. Rab7 regulates 
cargo trafficking to the lysosomes for degradation via late endosomes, cargo recycling 
through the Golgi back to the plasma membrane, autophagy, phagolysosome fusion and 
osteoclast-mediated bone resorption. 
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Functional role of Rab7 
   Rab7 plays a significant role in endocytic trafficking and other degradative pathways 
such as autophagy and phagocytosis (27, 29, 30). Rab7 regulated pathways are important 
for normal cell physiology as illustrated by the following examples. Firstly, Rab7 and its 
effectors are central to the regulation of growth factor signaling and receptor down 
regulation through lysosomal degradation (31-33). Increased receptor downregulation 
may be pertinent to reducing hyperactive signaling in cancers where expression of 
epidermal growth factor receptor is elevated and/or constitutively active, where Rab7 is 
also overexpressed (34, 35). Upregulation of active Rab7 may lead to modest increases in 
growth factor receptor degradation. 
   Secondly, Rab7 participates in phagocytic and autophagic processes. Rab7 facilitates 
the fusion of autophagosomes with lysosomes that is important in nutrient regulation, 
clearance of cytoplasmic protein aggregates and degradation of organelles (36-42). 
Imbalances in autophagy are associated with immune dysregulation, cancer, and 
neurodegeneration (43, 44).   Extracellular pathogens and dead cells engulfed into 
phagosomes are known to be cleared through a maturation phase requiring phagosome 
fusion with endosomes (45, 46). The maturation process is characterized by formation of 
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a late phagosome and a subsequent phagolysosome, thus degradation of pathogens and 
cellular debris are dependent on Rab7 (47, 48).  
   Thirdly, Rab7 is important for the biogenesis of secretory lysosomes such as 
melanosomes and lytic granules secreted by immune cells that are important in normal 
pigmentation and immune cell function.  Rab7 has been shown to associate with early 
and intermediate stage melanosomes during melanosomal transport (49-51). This was 
further illustrated in human amelanotic melanoma cells (SK-mel-24) where expression of 
dominant negative Rab7 impaired vesicular transport of tyrosinase and TRP-1 proteins 
from the trans-Golgi network to maturing melanosomes (52), and also in MMAc 
melanoma cells, where the GTP-bound (active) form of Rab7 promoted melanogenesis 
by regulating gp100 maturation (51). Secretory lysosome exocytosis also accompanies 
bone remodeling events during which formation of a ruffled border facilitated by Rac1 is 
accompanied by transport and fusion of acidic intracellular vesicles with the plasma 
membrane in a Rab7 regulated process (53-55). Improper transport of melanosomal and 
lytic substances can potentially be cytotoxic to cells coupled with defects in 
pigmentation, poor immune system regulation and bone defects. This therefore 
emphasizes the important role Rab7 is playing in secretory lysosome biogenesis and 
function.  
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   Fourthly, Rab7 is important for the regulation of lipid homeostasis and lipid signaling 
in the control of vesicle trafficking.  Proper sphingolipid (SLs) transport and metabolism 
is important for membrane structure, cell signaling, regulation of cell growth and the cell 
cycle and when aberrant leads to sphingolipid storage disorders that cause mental 
retardation and premature death (56-58). Nieman-Pick type C (NPC) disease is 
characterized the accumulation of sphingolipids in late endosomes and lysosomes in 
tissues such as liver, spleen and brain (59, 60). The defects in cholesterol and 
sphingolipid storage are dramatically improved by the overexpression of Rab7, which 
enhances intracellular trafficking of cholesterol and sphingolipids (61). Rab7 together 
with the lipid kinase hVps34/hVps15 (62) and the myotubularin lipid phosphatases 
(MTM1 and MTMR2) serves as a molecular switch controlling the sequential synthesis 
and degradation of endosomal PI(3)P important for the spatial and temporal regulation of 
vesicle budding and fusion (63, 64). Lipid homeostasis also involves the function of 
ORP1L which is a Rab7 effector.  In Mel JuSo cells cells, ORPIL was shown to act as a 
sensor of cholesterol accumulation in late endosomes in addition to transmitting 
information to the Rab7–RILP–p150 glued complex through the formation of 
endoplasmic reticulum– late endosome membrane contact sites (65).  Normal cellular 
lipid levels dictate processes ranging from vesicular trafficking, signaling to receptor 
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degradation among others, defects in which may result in human disease. These confirm 
the importance of Rab7 in lipid synthesis and trafficking.  
   Fifthly, Rab7 is important in regulating cell-cell adhesion. Cell differentiation is 
characterized by epithelial cells undergoing epithelial–mesenchymal transition (66). This 
change is marked by down-regulation and intracellular sequestration of E-cadherin and 
other cell-cell junction proteins that are later trafficked via the endocytic pathway to the 
lysosomes (66). Enhanced transport of ubiquitinated E-cadherin to the lysosomes occurs 
through hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) and v-Src-
induced activation of Rab7 mediated transport, thereby contributing to the regulation of 
cell-cell adhesion (67).  
    The enumerated Rab7 functions in endocytic membrane transport occur in different 
cellular contexts yet overall serve to regulate key cellular functions that dictate cell 
viability and differentiation.  All Rab7 functions depend on coordinated spatial and 
temporal interactions between Rab7 and other regulatory partner molecules as discussed 
further in the following section. 
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Rab7 and its accessory effector molecules 
   Membrane trafficking requires a series of discrete temporally and spatially regulated 
steps that include: 1) cargo selection and clustering, 2) vesicle coat protein recruitment, 
vesicle budding through the action of membrane curvature inducing proteins, 3) 
cytoskeleton mediated translocation, and 4) docking and fusion with the target 
membrane.  Rab GTPases are known to function in all aspects of transport through the 
sequential interaction with different effectors.  Rab7 interacts with multiple effector 
molecules to regulate endocytic transport, including proteins regulating phosphoinositide 
signaling, motor proteins controlling bidirectional cytoskeletal transport, proteasome 
subunits controlling degradation, among others (62, 63, 68-71) (Appendix B).  
   One of the best characterized Rab7 effector proteins is the Rab7 interacting lysosomal 
protein (RILP) which is important for cargo sorting and retrograde cytoskeletal 
translocation.  Upon RILP recruitment to late endosomes and lysosomes binds and 
prolongs the Rab7 activation (GTP bound state) (68, 72-76). A complex of Rab7 and 
RILP induces recruitment of dynein-dynactin motor complexes to Rab7-containing late 
endosomes and lysosomes (69, 77, 78). RILP in turn mediates the membrane recruitment 
of VPS22 and VPS36 of the ESCRT-II machinery, which is responsible for 
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multivesicular body formation through intraluminal vesicle invagination and important in 
exosome formation and growth factor receptor sorting (31, 79). Depletion of RILP leads 
to elevated levels of four late endosomal molecules (lysobisphosphatidic acid, Lamp1, 
CD63 and cation-independent mannose-6-phosphate receptors) besides inhibiting ligand-
mediated degradation of epidermal growth factor receptors [EGFRs] (31). Thus, Rab7 
together with RILP controls late endosomal sorting of lipids and proteins associated with 
cargo delivery. RILP has been shown to function in concert with ORP1L effector 
whereby, a complex involving RILP, Rab7, p150Glued and ORP1L activates microtubule 
(dynein) motors and initiates translocation of late endosomes on microtubules (80) to 
facilitate vesicular transport to lysosomes. 
    The ubiquitin–proteasome pathway is a well-known mechanism for the targeted 
degradation of cytosolic proteins (81, 82). The proteasome mediated by the α-subunit 
XAPC7 (also known as PSMA7, RC6-1, and HSPC) has been shown to interact 
specifically with Rab7 that aids in its recruitment to the membranes of multivesicular late 
endosomes (71, 82).  The XAPC7 interaction facilitates the connection between cargo 
sorting and degradative events.  
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    Rabring7 (Rab7-interacting ring finger protein) originally isolated using a CytoTrap 
system (83), is also a downstream effector protein of Rab7 involved in EGFR trafficking 
for lysosomal degradation through its E3 ligase activity. Overexpression of Rabring7 was 
shown to alter EGFR degradation besides inducing perinuclear aggregation of lysosomes 
(84, 85). High cellular levels of Rabring7 are also marked by enhanced accumulation of 
the acidotropic probe LysoTracker (83), a phenomenon which implicates Rabring7 
protein in lysosome biogenesis and receptor degradation.  Internalization of 
polyubiquitylated TrkA involves its interaction with Unc51.1 and p62, the atypical 
protein kinase C interacting protein and this degradative process is also thought to 
involve the Rabring7 effector. 
    Rab7 interacts with hVps34 kinase, its adaptor protein p150 and phosphatidylinositol 
3-kinase (18, 27, 63). The complex ensures regulated phosphatidylinositol 3-phosphate 
synthesis on early and late endosomes (62). Phosphatidylinositol 3-phosphate enriched 
membrane domains facilitate membrane fusion through the recruitment of FYVE domain 
containing proteins, and intraluminal vesicle sequestration of growth factors (86).  
Myotubularin phosphatase mediated degradation of phosphatidylinositol 3-phosphate 
terminates the signal and is accompanied by a requisite dissociation of the Rab7/Vps34 
complex (64).   
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    As illustrated by the given examples, coordinate interactions between Rab7 and 
multiple effector proteins cut across key processes that are crucial to cell function. 
Misregulation leads to various disease states such as cancer, neurodegenerative disease 
and cell infection by pathogens. Collectively, the data implicate Rab7 as an important 
small molecule target. 
Regulation of Rab7  
    The principal processes pertinent to regulation of Rab7 include prenylation and 
membrane insertion, nucleotide binding and hydrolysis, and effector protein interaction 
(Fig. 1) (28, 87). The function of Rab GTPases are primarily dictated by both proper 
membrane association and a nucleotide exchange mechanism that turns the protein on 
through GTP binding and off through GTP hydrolysis based on nucleotide dependent 
conformational changes. In mammalian cells, Rab7 can localize to late endosomes, 
lysosomes, cytosol, phagosomes, melanosomes and exosomes (27, 30, 37, 39, 52, 88, 89). 
Location of Rab7 at these sites depends on whether the GTPase is in the ‘active’ or 
‘inactive’ state. After translation, cytosolic GDP bound Rab7 undergoes post-
translational geranylgeranylation which enables it to associate reversibly with 
intracellular membranes and thus is critical to its biological function (90-97).  
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    The process of Rab7 geranylgeranylation proceeds in a sequential manner. Newly 
synthesized Rab7 protein first associates with Rab escort protein (REP-1) via its alpha-
subunit (98). Rab7 then interacts with the Rab binding platform of REP-1 via an extended 
interface involving the Switch 1 and 2 regions of Rab7 with the C terminus of the REP-1 
molecule functioning as a mobile lid covering a conserved hydrophobic patch of REP-1 
(99). The integrity of this interaction is significant since mutations in the REP-1 gene in 
humans have been associated with X-chromosome-linked defect, choroideremia, a 
progressive disease that inevitably culminates in complete blindness (99-102).   
    Once bound to Rab7, REP-1 presents the GTPase to the Rab geranylgeranyl 
transferase (RabGGTase) enzyme loaded with the isoprenoid donor geranylgeranyl 
pyrophosphate, GGpp (103). The enzyme then catalyzes covalent modification of the Rab 
protein at the C-terminal cysteine motifs with two geranylgeranyl (GG) moieties (98, 
104). The highly variable C-terminal domain of Rab7 contains two cysteine residues that 
are subject to prenylation (97, 105). The addition of lipid moieties on Rab7 is similar for 
all Rab proteins and is crucial for membrane recruitment (90-94). 
     Rab7 delivery to the target membrane involves release of GDI. This is accomplished 
by a membrane associated protein factor called GDI-displacement factor (GDF) (106). 
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GDFs are present either in the early secretory pathway or within the endocytic pathway 
(94). The current model has it that once delivered to the membrane and GDI extracted by 
GDF, Rab7 diffuses within the plane of the membrane and is then stabilized by relevant 
effector binding (107). This model still needs to be refined since there are studies 
suggesting that the necessity of GDF to extract GDI may not be thermodynamically 
tenable (96). Delivered GDP bound Rab7 can then undergo nucleotide exchange by 
losing its GDP for GTP in order to perform downstream functions. Following GEF 
catalyzed activation, Rab7 GTPase interacts in a temporally and spatially regulated 
manner with specific effector molecules (Appendix B). These include sorting adaptors, 
tethering factors, kinases, phosphatases and motor proteins that ensure cargo sorting, 
vesicle transport and fusion (2). Unlike Rab5 with a known GEF as Rabex5, the Rab7 
GEF is still under investigation. Ccz1-Mon1 acts as the yeast Ypt7 GEF(108), an 
orthologue of mammalian Rab7. Termination of Rab7 GTPase activation is achieved by 
intrinsic GTPase hydrolysis and GAP stimulated catalysis (109). Currently, some TBC 
domain containing proteins such as TBC1D5 and TBC1D15 have been identified as Rab7 
GAP (21, 109, 110).  
     Another regulatory mechanism with significant control on Rab7 activity is Rab5-Rab7 
conversion (Fig. 3). Conversion is thought to confer directionality to the membrane 
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trafficking events leading to membrane maturation (111-116). It involves HOPS complex 
mediated recruitment of Rab7 into Rab5 positive organelles (112, 113). There are 
suggestions that hVps39 may also be involved in this process as part of the complex (108, 
114, 115).  
Association of the Rab7 GTPase with human disease 
    Rab7 has been associated with different types of diseases ranging from those due to 
mutations in the Rab7 encoding gene to others that may result from manipulation of the 
transport role of Rab7 by pathogens (117). Diseases associated with Rab7 arising from 
genetic mutations tend to be primarily peripheral neuropathies. The latter can be caused 
by mutations in multiple genes required for axon viability or Schwann cell dependent 
myelination (118, 119).  Charcot-Marie-Tooth type 2B (CMT2B) disease (also known as 
hereditary sensory neuropathy 1C) causes axonal degeneration and has been linked to 
four missense mutations in Rab7 gene (29, 33, 120-122). The mutations target highly 
conserved residues that reside on the surface of Rab7 and affect nucleotide exchange (33, 
123-125). In neuronal N2A and PC12 cell lines, expression of the mutant proteins 
inhibits neurite outgrowth (126).  Such changes in neuronal differentiation are likely due 
to prolonged phosphorylation of the TrkA receptor and altered Erk nuclear signaling 
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caused by the expression of the mutant Rab7 proteins (33). Patients with CMT2B disease 
usually manifest severe sensory loss, distal muscle weakness and a high frequency of foot 
ulcers and infections with frequent digit amputations (127, 128).  Because CMT2B is an 
autosomal dominant disease, it is predictable that selective inhibition of the mutant 
protein or enhancement of wild-type Rab7 activity might be beneficial therapeutic 
interventions. 
     With respect to the usual Rab7 role, CMT2B mutant proteins may potentially alter 
Rab5-Rab7 conversion, Rab7-effector protein interactions and therefore impact Rab7-
regulated trafficking to and from the cell body that are required for maintenance of axon 
viability and normal impulse transmission. For example the CORVET and HOPS protein 
complexes identified in yeast and conserved in mammalian systems are thought to enable 
transition of cargo from early to late endosomes and lysosomes (129).  GTP-bound Rab7 
recruits the dynein/dynactin motor complex through the Rab interacting lysosomal 
protein (RILP) and in conjunction with Rabring7 promotes growth factor degradation 
(68, 83, 85).  
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    Taken together, the enumerated roles of Rab7 in addition to its regulation and effector 
protein interactions coupled with its overexpression in cancer and mutant Rab7 
associated with peripheral neuropathies, make Rab7 an important candidate for small 
molecule modulation. Such molecules could have utility both for dissecting the 
mechanistic details of processes governed by Rab7, as well as for the future development 
of targeted therapies (18, 130). This by extension may provide a platform for small 
molecule modulation of other members of the Rab family, a growing number of which 
are implicated in diseases ranging from pigmentation and bleeding disorders to bone 
diseases and thereby address questions that remain regarding ubiquitous and cell type 
specific functions of Rab GTPases and how these may contribute to disease pathogenesis. 
More so, this approach may provide detailed understanding of how Rab GTPases 
coordinate with regulatory proteins, downstream effector proteins and other GTPases to 
effect cargo selection, vesicle formation, translocation through cytoskeletal networks, and 
targeted vesicle fusion (131, 132). Thus, we sought to investigate how Rab7 function may 
be modulated by a small molecule both in the context of understanding normal Rab7 
function as well as in terms of characterizing Rab7 as a potential therapeutic target. This 
is a new area that has not been investigated despite the important cellular functions and 
disease pathologies associated with Rab7. For this purpose, I used a sulfur based small 
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chemical molecule herein called; 2-(benzoylcarbamothioylamino)-5,5-dimethyl-4,7-
dihydrothieno[2,3-c]pyran-3-carboxylic acid (Pubchem #: CID1067700). 
Materials and Methods 
Reagents 
    Reagents used in this study were obtained from Sigma unless otherwise indicated. 
Sephadex G-25, glutathione (GSH) Sepharose 4B, and Superdex peptide beads (13 µm 
with an exclusion limit of 7 kDa) were from Amersham Biosciences. BODIPY (4,4-
difluoro-4-bora-3a,4a-diaza-s-indacene or dipyrromethene boron difluoride) nucleotide 
analogues (BODIPY FL GTP 2’-(or 3’)-O-[N-(2-aminoethyl)urethane] G-35778 and 
BODIPY FL GDP 2’-(or-3’)-O-[N-(2-aminoethyl)urethane], G-22360) were from 
Invitrogen Molecular Probes (Carlsbad, CA, USA). Concentrations of BODIPY 
nucleotides were based on absorbance measurements and an extinction coefficient value 
of 80,000 M-1 cm-1. 2-(benzoylcarbamothioylamino)-5,5-dimethyl-4,7- 
dihydrothieno[2,3-c]pyran-3-carboxylic acid with compound identification number 
(CID1067700) was from ChemDiv. 
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Expression and purification of GST-Rab7 
    GST–Rab7 protein was expressed in E. coli BL21 (DE3). Cultures were grown at 37°C 
to a bacterial density of 0.5-0.7 absorbance units at 595 nm and protein induced by 
transfer to room temperature and addition of 0.2 mM isopropyl-beta-D-1-
thiogalactopyranoside (IPTG) for 16-18 h to maximize yield of properly folded active 
fusion protein. Purification of GST-Rab7 was performed according to standard 
procedures and as previously described (133).  
Synthesis of glutathione beads for flow cytometry assay 
    High GSH density beads used for flow cytometry were synthesized by loading 
Superdex peptide beads with GSH as previously reported (133, 134). 
Immobilization of Rab7 on GSH beads for flow cytometry 
     All nucleotide binding to Rab7 and measurements were performed in the HPS buffer 
(30 mM Hepes, pH 7.5, 20 mM NaCl and 100 mM KCl) containing 1 mM EDTA. A 
BectonDickinson FACScan flow cytometer with a 488-nm excitation laser and standard 
detection optics was used for all assays (133). Pure GST-Rab7 protein was incubated in 
96-well plates at 4°C overnight with 105 GSH beads in a total volume of 100 µl of HPS 
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buffer containing 1 mM EDTA and 1 mM dithiothreitol (DTT) added fresh. Unbound 
protein was removed by centrifugation washes by spinning GST-Rab7 bound to GSH 
beads twice at 800 g followed by resuspension of washed protein in fresh HPS buffer 
containing 1 mM EDTA and 1 mM dithiothreitol (DTT). 
Dose response or competition binding assays  
     Dose response assays were conducted in two different modes. In the first case, 5x103 
GSH beads loaded with GST-Rab7 were incubated with a fixed concentration of 
nucleotide (GDP or GTP) for 1 h in the presence of 1% DMSO (final) or increasing 
concentrations of CID1067700 (10-3 – 100 µM) in 1% DMSO and a total volume of 20 µl 
on a 96-well plate. A stock solution of CID1067700 (10 mM) was prepared in 100% 
DMSO and stored in single use aliquots at -80°C. In the second mode, 5x103 GSH beads 
loaded with GST-Rab7 protein were incubated for 2 h 15 min at 4 °C with varying 
concentrations of fluorescent guanine nucleotide (0–2 µM) in a total volume of 20 µl on a 
96-well plate in the presence of either 1 % DMSO or a fixed CID1067700 concentration 
(0.1 – 1µM). For measurements on the flow cytometer, samples were transferred to a 
falcon tube (BD Bioscience) for flow cytometry and were diluted at least 10-fold in HPS 
buffer. This dilution step was necessary to ensure discrimination of bead-associated 
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fluorescence and background fluorescence of soluble proteins and also ensured sufficient 
sample volume for the measurement. 
Nucleotide dissociation assays in the presence of CID1067700 
     Nucleotide dissociation under equilibrium conditions was accomplished by first 
incubating 1.5x105 GSH bead bound GST-Rab7 with fixed BODIPY-GTP (100 nM) or 
BODIPY-GDP (40 nM) for 2hr 15 min at 4 oC followed by initiating release of bound 
nucleotide with either unlabeled GDP  (10 µM) or CID1067700 (10 µM). As a negative 
control, GST-Rab7 was preloaded with unlabelled GDP (1 mM) for 2hr 15 min at 4oC 
prior to adding BODIPY-GTP or BODIPY–GDP at the above concentrations for a further 
2hr 15 min and then similarly initiating release of bound BODIPY-linked nucleotide with 
unlabeled GDP (10 µM) to obtain fluorescence for non-specific binding under 
equilibrium binding conditions. This low level bead associated fluorescence was 
subtracted from specific binding to obtain accurate measurement of the off rates.  
Molecular docking of CID1067700 on Rab7 
    Docking calculations were performed using OpenEye Fred (Fred, version 2.2.5, 
OpenEye Scientific Software, Inc., Santa Fe, NM, USA, www.eyesopen.com, 2010) 
docking software. Rab7 crystal structures (PDB code: 1T91 GDP-conformer, 1VG8 
GNP-conformer) were used to dock CID1067700 on Rab7 for the wild type. Chemgauss3 
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scoring function was used to evaluate ligand binging potential. Docking simulations 
provide only a qualitative assessment of binding probability of our ligand to Rab7 and 
should be examined with care, however the results indicate that CID1067700 can 
potentially bind to Rab7 nucleotide binding site and no steric constrains were observed 
Data analyses  
    All data processing and analyses employed GraphPad Prism software (GraphPad 
Software, San Diego). For kinetic experiments, raw data acquired were first processed 
using IDLE query software (obtained from University of New Mexico Center for 
Molecular Discovery, UNM CMD) before further analysis using GraphPad Prism. All 
experiments are representative of at least three independent trials.  
Synthesis of CID1067700 derivatives for structure activity analyses 
    Structure activity relationship (SAR) was performed to understand the relationship 
between the chemical structure of CID1067700 and its activity. A lot of times, the 
activity of a small molecule can be a pharmacological response, binding, toxicity or any 
other quantifiable event. In our context, the activity of interest was pharmacological 
response marked by modulation of nucleotide binding by Rab7 by CID1067700. 
Derivatives of CID1067700 were synthesized and analyzed for purity by collaborating 
laboratory at University of Kansas. The steps involved were carried out using standard 
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chemical synthesis protocol. Below is a sequential summary of the methods employed. 
Chemistry and analytical details 
    1H and 13C NMR spectra were recorded on a Bruker AM 400 spectrometer (operating 
at 400 and 101 MHz respectively) in CDCl3 with 0.03% TMS as an internal standard or 
DMSO-d6. The chemical shifts (d) reported are given in parts per million (ppm) and the 
coupling constants (J) are in Hertz (Hz). The spin multiplicities are reported as s = 
singlet, br. s = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet 
and multiplet. The LCMS analysis was performed on an Agilent 1200 RRL 
chromatograph with photodiode array UV detection and an Agilent 6224 TOF mass 
spectrometer. The chromatographic method utilized the following parameters: a Waters 
Acquity BEH C-18 2.1 x 50 mm, 1.7 um column; UV detection wavelength = 214 nm; 
flow rate = 0.4 ml/min; gradient = 5 - 100% acetonitrile over 3 minutes with a hold of 0.8 
minutes at 100% acetonitrile; the aqueous mobile phase contained 0.15% ammonium 
hydroxide (v/v). The mass spectrometer utilized the following parameters: an Agilent 
multimode source which simultaneously acquires ESI+/APCI+; a reference mass solution 
consisting of purine and hexakis (1H, 1H, 3H-tetrafluoropropoxy) phosphazine; and a 
make-up solvent of 90:10:0.1 MeOH:Water:Formic Acid which was introduced to the LC 
flow prior to the source to assist ionization. Melting points were determined on a 
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Stanford Research Systems OptiMelt apparatus. Synthesized analogs were prepared by 
the general route depicted in Fig. 5.  Stepwise procedures for all synthesized analogs and 
intermediates are described.  Analytical characterization is provided for all tested 
commercial and synthetic compounds itemized in this section. 
Figure 5. General scheme used for synthetic analogs  
  
 
 
   tert-Butyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate. Following a 
previously reported procedure. Tetrahydro-4H-pyran-4-one (0.28 mL, 3.0 mmol, 1 
equiv.), tert-butyl cyanoacetate (0.47 mL, 3.3 mmol, 1.1 equiv.), sulfur (0.106 g, 3.30 
mmol, 1.1 equiv.), and morpholine (0.39 mL, 4.5 mmol, 1.5 equiv.) were dissolved in 
EtOH (9 mL) and stirred at 50 oC1 for 16 h. The solvent was removed and water (7 mL) 
was added. The product was extracted with EtOAc (2 × 7 mL) and purified by 
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preparatory HPLC (0-20% EtOAC:hexanes).  The product was isolated as a clear, pale 
yellow oil (0.77 g, quantitative yield). 1H NMR (400 MHz, CDCl3) δ 5.98 (s, 2H), 4.55 (t, 
J = 2.0 Hz, 2H), 3.90 (t, J = 5.6 Hz, 2H), 2.79 (ddd, J = 7.6, 3.8, 2.0 Hz, 2H), 1.54 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ 165.38, 161.65, 130.33, 114.60, 106.76, 80.37, 
65.20, 64.66, 28.57, 27.94. 
 
 
 
     tert-Butyl 2-(3-benzoylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-
carboxylate. tert-Butyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate 
(0.099 g, 0.39 mmol, 1 equiv.) and PhCONCS (0.06 mL, 0.4 mmol, 1 equiv.) were 
dissolved in THF (2 mL) and stirred at 50 oC for 16 h. The solvent was removed and the 
product was purified by preparatory HPLC (0-30% EtOAC:hexanes). The product was 
isolated as a white solid (0.131 g, 80% yield). 1H NMR (400 MHz, CDCl3) δ 14.75 (s, 
1H), 9.21 (s, 1H), 7.92 (dd, J = 5.2, 3.3 Hz, 2H), 7.64 – 7.57 (m, 1H), 7.54 – 7.46 (m, 
2H), 4.71 (s, 2H), 3.94 (t, J = 5.6 Hz, 2H), 2.90 (t, J = 5.6 Hz, 2H), 1.63 (s, 9H). 13C 
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NMR (101 MHz, CDCl3) δ 173.72, 165.23, 164.54, 147.15, 133.48, 131.81, 129.36, 
129.04, 127.77, 125.77, 117.76, 82.36, 65.20, 64.71, 28.51, 27.38. 
 
 
      2-(3-benzoylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid 
(SID 99381129, CID 46916266). To a solution of tert-Butyl 2-(3-benzoylthioureido)-5,7-
dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (0.104 g, 0.25 mmol, 1 equiv.) in DCM (10 
mL) was added TFA (2 mL, 26 mmol, 100 equiv.), and the reaction was stirred at rt for 
16 h. The solvent was removed and the product was triturated with 1:1 Et2O/hexanes (25 
mL) and filtered. The product was purified by mass-directed reverse-phase 
chromatography and isolated as a white solid (3 mg, 3% yield). 1H NMR (400 MHz, 
CDCl3) δ 14.92 (br s, 1H), 9.02-9.09 (m, 1H), 7.83-7.91 (m, 1H), 7.55-7.66 (m, 2H), 
7.41-7.50 (m, 2H), 7.19-7.23 (m, 1H), 4.69-4.76 (m, 2H), 3.92-3.98 (m, 2H), 2.88-3.03 
(m, 2H). LCMS retention time: 2.955 min; LCMS purity at 215 nm = 100%. HRMS m/z 
calculated for C16H15N2O4S2 [M++1]: 363.0468, found 363.0464. 
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   tert-Butyl 2-amino-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate. 
A mixture of 2,2-dimethyldihydro-2H-pyran-4(3H)-one (0.300 g, 2.34 mmol, 1 eq), tert-
butyl cyanoacetate (0.37 mL, 2.57 mmol, 1.1 eq), sulfur (0.083 g, 2.57 mmol, 1.1 eq), 
morpholine (0.30 mL, 3.51 mmol, 1.5 eq), and ethanol (7 mL) was heated at 50 °C for 16 
h.  The reaction mixture was then filtered, and the filter cake washed with ethyl acetate 
(20 mL).  Purification by silica gel chromatography (0-20% EtOAc:Hex ramp over 20 
min) afforded the desired product tert-butyl 2-amino-5,5-dimethyl-5,7-dihydro-4H-
thieno[2,3-c]pyran-3-carboxylate as a yellow solid (0.631 g, 2.23 mmol, 95 % yield).  1H 
NMR (400 MHz, CDCl3) δ 5.88 (s, 2H), 4.52 (t, J = 1.9, 2H), 2.64 (t, J = 1.9, 2H), 1.53 
(s, 9H), 1.26 (s, 6H). 
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     tert-Butyl 2-(3-benzoylureido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-
carboxylate. tert-Butyl 2-amino-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-
carboxylate (0.116 g, 0.41 mmol, 1 equiv.) and PhCONCO (0.06 mL, 0.5 mmol, 1.2 
equiv.) were dissolved in THF (2 mL) and stirred at 50 oC for 16 h. The solvent was 
removed and the product was purified by preparatory HPLC (0-40% EtOAC:hexanes). 
The product was isolated as a white solid (0.105 g, 59% yield). 1H NMR (400 MHz, 
CDCl3) δ 13.26 (s, 1H), 9.81 (s, 1H), 8.13 (d, J = 7.0 Hz, 2H), 7.65 (d, J = 6.7 Hz, 3H), 
4.72 (s, 2H), 2.75 (s, 2H), 1.64 (s, 9H), 1.32 (s, 6H). 
 
 
   2-(3-Benzoylureido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic 
acid (SID 99381130, CID 46916265). To a solution of tert-butyl 2-(3-benzoylureido)-
5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (0.105 g, 0.24 mmol, 1 
equiv.) in DCM (10 mL) was added TFA (0.5 mL, 6.5 mmol, 27 equiv.), and the reaction 
was stirred at rt for 5 days. The solvent was removed under reduced pressure and the 
product was purified by preparatory HPLC (0-5% MeOH/DCM), followed by mass-
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directed reverse-phase chromatography and isolated as a white solid (6 mg, 7% yield). 1H 
NMR (400 MHz, DMSO) δ 13.11 (s, 1H), 11.39 (s, 1H), 8.05 – 7.99 (m, 2H), 7.69 – 7.63 
(m, 1H), 7.55 (t, J = 7.7 Hz, 2H), 4.62 (s, 2H), 2.71 (s, 2H), 1.22 (s, 6H). LCMS retention 
time: 2.872 min; LCMS purity at 215 nm = 100%. HRMS m/z calculated for 
C18H19N2O5S [M++1]: 375.1009, found 375.1013. 
 
 
5,5-dimethyl-2-(2-phenylacetamido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-
carboxylic acid  (SID 99381117, CID 740871). 5,5-Dimethyl-2-(2-phenylacetamido)-
5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid was purchased from ChemBridge 
(CAS 303966-15-6) and purified by mass-directed reverse-phase chromatography and 
isolated as a white solid (3 mg, 100% purity). 1H NMR (400 MHz, CDCl3) δ 10.88 (s, 
1H), 7.43 – 7.37 (m, 2H), 7.33 (dd, J = 6.7, 4.3 Hz, 3H), 4.72 (s, 2H), 3.85 (s, 2H), 2.85 
(s, 2H), 1.35 (s, 6H). LCMS retention time: 3.045 min; LCMS purity at 215 nm = 100%. 
HRMS m/z calculated for C18H20NO4S [M++1]: 346.1108, found 346.1110. 
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  Methyl 2-(3-benzoylthioureido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-
carboxylate (SID 99381118, CID 1251121). To a combined mixture of methyl 2-amino-
5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (ChemBridge, CAS 
713111-73-0, 31 mg, 0.13 mmol, 1 equiv.) and PhCONCS (0.02 mL, 0.15 mmol, 1.2 
equiv.) was added THF (0.7 mL).  The resulting solution was stirred at 50 oC for 3 days. 
The solvent was then removed under reduced pressure and the crude product was 
triturated with hexanes, filtered, and rinsed with hexanes (4 × 5 mL). The product was 
further purified by preparatory HPLC (0-50% EtOAC:hexanes) and isolated as a white 
solid (38 mg, 72% yield). 1H NMR (400 MHz, CDCl3) δ 14.83 (s, 1H), 9.14 (s, 1H), 7.98 
(dd, J = 8.4, 1.2 Hz, 2H), 7.72 – 7.63 (m, 1H), 7.56 (dd, J = 10.5, 4.8 Hz, 2H), 4.77 (t, J = 
1.5 Hz, 2H), 4.04 (s, 3H), 2.85 (s, 2H), 1.35 (s, 6H). LCMS retention time: 3.508 min; 
LCMS purity at 215 nm = 96%. HRMS m/z calculated for C19H21N2O4S2 [M++1]: 
405.0937, found 405.0942. 
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   2-(3-benzoylthioureido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-
carboxylic acid (SID 85747738/ CID 1067700).  2-(3-benzoylthioureido)-5,5-dimethyl-
5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid was purchased from Chemdiv Inc. 
(CAS 314042-01-8) and purified by mass-directed reverse-phase chromatography to 
yield a white solid (6 mg). 1H NMR (400 MHz, DMSO) δ 14.84 (s, 1H), 13.39 (s, 1H), 
11.81 (s, 1H), 7.98 (dd, J = 1.2, 8.4, 2H), 7.74 – 7.62 (m, 1H), 7.55 (t, J = 7.7, 2H), 4.67 
(s, 2H), 2.75 (s, 2H), 1.24 (s, 6H). 13C NMR (101 MHz, DMSO) δ 174.43, 166.86, 
165.35, 146.72, 133.08, 132.06, 129.10, 128.75, 128.41, 124.09, 116.50, 70.14, 58.82, 
37.27, 26.19. LCMS retention time: 1.871 min; LCMS purity at 214 nm = 92.8%. HRMS 
m/z calculated for C18H19N2O4S2 [M++1]: 391.0781, found 391.0777. 
 
 
    2-(3-benzoylthioureido)-5-methyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic 
acid (SID 9931128/ CID 46916263).  To tert-butyl 2-(3-benzoylthioureido)-5-methyl-5,7-
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dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (0.028 g, 0.065 mmol, 1 eq.) was added a 
40% v/v solution of trifluoroacetic acid in dichloromethane (2.5 mL). After stirring the 
solution for 4 hours at rt, the solvent was evaporated in vacuo, and the residue purified by 
reverse-phase chromatography to yield the product as a white semi-solid (0.011 g, 0.029 
mmol, 46% yield).  1H NMR (400 MHz, Acetone) δ 8.07 (d, J = 7.4, 2H), 7.68 (t, J = 7.0, 
1H), 7.56 (t, J = 7.5, 2H), 4.76 (q, J = 14.7, 2H), 3.82 – 3.68 (m, 1H), 3.05 (d, 1H), 1.47 
(d, J = 6.5, 1H), 1.32 (d, J = 6.1, 3H).  13C NMR (126 MHz, Acetone) δ 175.37, 166.92, 
165.37, 161.89, 148.65, 134.12, 133.28, 131.39, 129.62, 129.28, 126.49, 71.61, 65.11, 
35.05, 21.82.  LCMS retention time: 3.095 min; Purity at 214 nm = 93.3%.  HRMS m/z 
calculated for C17H17N2O4S2 [M+ + 1] 377.0624, found 377.0622. 
 
 
 
   tert-butyl 2-amino-5-methyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate.  A 
mixture of 2-methyldihydro-2H-pyran-4(3H)-one (0.320 g, 2.80 mmol, 1 eq), tert-butyl 
cyanoacetate (0.44 mL, 3.08 mmol, 1.1 eq), sulfur (0.099 g, 3.08 mmol, 1.1 eq), 
morpholine (0.36 mL, 4.21 mmol, 1.5 eq), and ethanol (7 mL) was heated at 50 °C for 16 
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hours.  The reaction mixture was then filtered, and the filter cake washed with ethyl 
acetate (20 mL).  Purification by silica gel chromatography (0-30% EtOAc:Hex ramp 
over 20 min) afforded the desired product tert-butyl 2-amino-5-methyl-5,7-dihydro-4H-
thieno[2,3-c]pyran-3-carboxylate as a pale yellow solid (0.745 g, 2.77 mmol, 99 % yield).  
1H NMR (400 MHz, CDCl3) δ 5.90 (s, 2H), 4.71 – 4.49 (m, 2H), 3.82 – 3.65 (m, 1H), 
2.86 – 2.73 (m, 1H), 2.52 – 2.37 (m, 1H), 1.52 (d, J = 1.4, 9H), 1.31 (dd, J = 2.1, 6.2, 
3H).   
 
 
   tert-butyl 2-(3-benzoylthioureido)-5-methyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-
carboxylate.  To a solution of tert-butyl 2-amino-5-methyl-5,7-dihydro-4H-thieno[2,3-
c]pyran-3-carboxylate (0.104 g, 0.386 mmol, 1 eq) in dry ethanol (1 mL)under argon was 
added benzoyl isothiocyanate (0.15 mL, 1.08 mmol, 2.8 eq).  The mixture was heated at 
reflux for 16 hours.  The solvent was evaporated in vacuo. Purification by reverse-phase 
chromatography (10-100% CH3CN: Water ramp over 20 min) afforded the desired 
product tert-butyl 2-(3-benzoylthioureido)-5-methyl-5,7-dihydro-4H-thieno[2,3-c]pyran-
3-carboxylate as a pale yellow oil (0.057 g, 0.132 mmol, 34 % yield).  1H NMR (400 
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MHz, DMSO) δ 14.72 (s, 1H), 11.89 (s, 1H), 8.06 – 7.95 (m, 2H), 7.69 (t, J = 7.4, 1H), 
7.57 (t, J = 7.7, 2H), 4.78 (d, J = 14.8, 1H), 4.66 (d, J = 15.0, 1H), 3.80 – 3.63 (m, 1H), 
2.93 (d, J = 16.7, 1H), 2.50 – 2.44 (m, 1H), 1.59 (s, 9H), 1.30 (d, J = 6.1, 3H). 
 
 
   tert-butyl 5,5-dimethyl-2-(3-phenylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-
3-carboxylate. .  To a solution of tert-butyl 2-amino-5,5-dimethyl-5,7-dihydro-4H-
thieno[2,3-c]pyran-3-carboxylate (0.100 g, 0.353 mmol, 1 eq) in dry tetrahyrofuran (5 
mL) under argon was added phenyl isothiocyanate (0.05 mL, 0.388 mmol, 1.1 eq).  The 
mixture was heated at reflux for 16 hours.  The solvent was evaporated in vacuo. 
Purification by reverse-phase chromatography (0-100% CH3CN: Water ramp over 20 
min) afforded the desired product tert-butyl 5,5-dimethyl-2-(3-phenylthioureido)-5,7-
dihydro-4H-thieno[2,3-c]pyran-3-carboxylate as a yellow solid (0.045 g, 0.108 mmol, 30 
% yield).  1H NMR (400 MHz, DMSO) δ 11.92 (s, 1H), 11.05 (s, 1H), 7.50 (d, J = 7.6, 
2H), 7.42 (t, J = 7.9, 2H), 7.26 (t, J = 7.3, 1H), 4.61 (s, 2H), 2.65 (s, 2H), 1.53 (s, 9H), 
1.23 (s, 6H). 
 
 46 
 
   5,5-dimethyl-2-(3-phenylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-
carboxylic acid (SID 99381127/ CID 1280844).  To 5,5-dimethyl-2-(3-
phenylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid (0.037 g, 0.088 
mmol, 1 eq.) was added a 40% v/v solution of trifluoroacetic acid in dichloromethane 
(2.5 mL). After stirring the solution for 4 hours at rt, the solvent was evaporated in vacuo 
and the residue purified by reverse-phase LCMS to yield the product as a white solid 
(0.020 g, 0.065 mmol, 63% yield).  1H NMR (400 MHz, Acetone) δ 7.97 (d, J = 7.7, 2H), 
7.88 (t, J = 7.7, 2H), 7.73 (t, J = 6.9, 1H), 4.32 (s, 2H), 3.11 (s, 2H), 1.73 (s, 6H).  LCMS 
retention time: 3.113 min; Purity at 214 nm = 100%.  HRMS m/z calculated for 
C17H19N2O3S2 [M+ + 1] 363.0832, found 363.0829. 
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Results  
Identification of CID1067700 as an inhibitor of nucleotide binding by Rab7 
    CID1067700 was identified as an inhibitor of GTP-binding using a high throughput 
screen that was described previously in the context of an allosteric Rho GTPase inhibitor 
(135). Briefly, six sets of beads (each with a unique red fluorescence intensity) were 
individually coated with six representative GST-tagged Ras-related GTPases (Cdc42 wt, 
Rac1wt, Rac1Q61L, Rab2 wt, Rab7wt, and H-Ras wt) (Fig. 6a). The individually 
conjugated beads were then assayed in the presence of individual compounds in the 
Molecular Libraries Small Molecule Repository using HyperCyt flow cytometry to 
identify molecules that altered the binding of fluorescent nucleotide to Ras-family 
GTPases (136). CID1067700 (Fig. 6b), was identified as a hit that decreased fluorescent 
nucleotide (GTP) binding in the primary screen and was confirmed in secondary, 
multiplex dose response assays to have an EC50 of 20-500 nM and at least 40% inhibition 
against all tested GTPases (Fig. 6c). CID1067700 was the only compound identified in 
the screen to have significant inhibitory activity against the Rab GTPases (Rab2 and 
Rab7). Because of its pronounced inhibitory effect (>80%) on Rab7 and the absence of 
any known chemical inhibitors for Rab-family GTPases, I further characterized the 
mechanism of CID1067700 inhibition using Rab7 as a model protein.  
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Figure 6. Identification of CID1067700 as a pan GTPase inhibitor using high-
throughput screening on small GTPases. (a) Schematic diagram of the bead based 
assay used to measure fluorescent guanosine triphosphate (GTP) binding by flow 
cytometry to glutathione-S-transferase (GST)–GTPase chimeras immobilized on GSH-
beads. For HTS beads of varying red fluorescence intensities were used as identifiers for 
individual protein-conjugated bead sets. (b) Chemical structure of CID1067700 an 
inhibitor of nucleotide binding. 
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Figure 6. (c) Activity of CID1067700 against multiple GTPases measured as residual 
nucleotide binding activity (BODIPY-GTP, 100 nM) in the presence of increasing 
concentrations of compound. (d) Nanomolar concentrations of CID1067700 inhibit 
Rab7wt protein nucleotide binding; BODIPY-GTP (100 nM, filled squares) and 
BODIPY-GDP (40 nM, filled triangles). 
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Dose dependent inhibition of Rab7 nucleotide binding by CID1067700  
    Single-plex dose response measurements were used to determine the effect of 
CID1067700 on nucleotide binding by Rab7 small GTPase. To achieve this, the 
BODIPY-GDP and BODIPY-GTP concentrations in the assay were fixed to the 
previously determined equilibrium dissociation constants (Kd=100 nM BODIPY-GTP; 
Kd=40 nM BODIPY-GDP) for the wild-type (wt) Rab7 protein (133). Increasing 
CID1067700 concentrations resulted in strong inhibition of both BODIPY-GDP and 
BODIPY-GTP binding by Rab7wt with EC50 values of 25 nM for BODIPY-GTP and 40 
nM for BODIPY-GDP (Fig. 6d). The deduced efficacy of inhibition was 80% for 
BODIPY-GTP and 60% for BODIPY-GDP. These results demonstrate high efficacy and 
potency of the CID1067700 molecule with respect to inhibition of Rab7 nucleotide 
binding. Maximum inhibition by CID1067700 occurred at 1-10 µM CID1067700 
concentration range. Lower inhibitory efficacy against BODIPY-GDP binding may either 
represent a preference for one nucleotide conformer over another by Rab7 or the 
established higher affinity of Rab7 for GDP than for GTP (133, 137).  
    Inhibition of Rab7wt nucleotide binding by CID1067700 could be effected through 
allosteric or competitive binding. To distinguish between the two scenarios, we tested the 
inhibition of Rab7wt by CID1067700 under conditions where CID1067700 concentration 
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was held at a fixed concentration (100-200 nM) while increasing the concentration of the 
fluorescent nucleotide competitor (Fig. 7a-h). These values were equivalent to 
approximately 5 times the observed EC50 for CID1067700 using each of the two 
nucleotides. The inhibitory effect of CID1067700 was most pronounced at lower 
nucleotide concentrations, resulting in an overall rightward shift of the dose response 
curves (Fig. 7b, d). Significantly, both control (DMSO only) and inhibitor (CID1067700 
treated) curves had statistically similar Bmax values that correspond to the number of 
binding sites on Rab7 (Fig. 7a, c). Thus, at high concentrations, the nucleotide out 
competes the CID1067700 compound for the binding pocket, accounting for the Bmax 
values that are not statistically different. In contrast, there was ≤3-fold increase in the 
observed EC50 for both nucleotides in the presence of CID1067700 indicating 
competition of nucleotides by the inhibitor. Calculated inhibitor constants (Ki) for both 
nucleotides (Table 1) show a 2-fold increase between inhibition of BODIPY-GTP and 
BODIPY-GDP confirming that CID1067700 is better at inhibiting BODIPY-GTP 
binding than BODIPY-GDP binding. Analysis of the constitutively active Rab7Q67L and 
dominant negative Rab7T22N mutants, that mimic the GTP-bound and GDP-bound 
conformers respectively showed that both were similarly inhibited by CID1067700 (Fig. 
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7e-h). The composite data suggest that the CID1067700 compound and the nucleotide 
most likely compete for the nucleotide binding pocket of Rab7. 
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Figure 7. CID1067700 competitively inhibits BODIPY-linked nucleotide binding by 
wild type and mutant forms of Rab7. (a-b) CID1067700 (100 nM) does not alter 
Rab7wt Bmax for BODIPY-GTP, but does alter apparent EC50 for GTP (filled squares); 
observed as a rightward shift of log plot of BODIPY-GTP binding by Rab7wt. (c-d) 
CID1067700 (200 nM) does not alter Rab7wt Bmax for BODIPY-GDP; but does alter 
apparent EC50 for GDP (filled triangles); observed as rightward shift of log plot of 
BODIPY-GDP binding by Rab7wt.  
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Figure 7. (e-f). CID1067700  (100 nM) does not alter constitutively active Rab7Q67L 
mutant Bmax for BODIPY-GTP, but does alter apparent EC50 for GTP (filled squares); 
observed as a rightward shift of log plot of BODIPY-GTP binding by Rab7Q67L. (g-h) 
CID1067700 (200 nM) does not alter Rab7T22N Bmax for BODIPY-GDP; but does alter 
apparent EC50 for GDP (filled triangles); observed as rightward shift of log plot of 
BODIPY-GDP binding by Rab7T22N. In all experiments, equilibrium binding reactions 
performed in 1% DMSO served as the controls (open circles). 
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Table 1. Equilibrium binding parameters deduced from Figure 7. 
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CID1067700 does not affect nucleotide release by Rab7 
   To further confirm the mode of Rab7 nucleotide inhibition by CID1067700, we 
analyzed the fluorescent nucleotide dissociations rates from Rab7 in the presence of 
CID1067700. The experiment was carried out by pre-binding BODIPY-GTP or –GDP to 
GST-tagged Rab7 protein up to equilibrium nucleotide exchange point and then assaying 
for the loss of fluorescence over time occasioned by the release of bound nucleotide (Fig. 
8a-d). As a competitor, we used CID1067700 (10 µM) or unlabeled GDP (10 µM).  
Dissociation rate constants were calculated from data fit to exponential functions using 
Prism software. Koff values of Rab7wt obtained at room temperature were statistically 
similar between unlabeled GDP and CID1067700 competitor for both BODIPY-GTP or –
GDP (Table 1).  Together the data confirm that the CID1067700 compound has no effect 
on the rate of release of bound fluorescent GTP or GDP by Rab7, ruling out allosteric 
binding of the CID1067700 inhibitor in preference to competitive binding to the 
nucleotide pocket.  
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Figure 8: CID1067700 has no effect on the rate of release of bound BODIPY-linked 
nucleotide by wild type Rab7 under equilibrium binding conditions. (a) Rab7 was 
pre-incubated with BODIPY-GTP (100 nM) for 2 h 15 min at 4°C, conditions that allow 
nucleotide binding to equilibrium. Dissociation assays were initiated by dilution +/- the 
addition of either CID1067700 (10 µM) or unlabeled GDP (10 µM) and decrease in 
fluorescence due to nucleotide dissociation was measured in real time. (b) Two-phase 
exponential analysis of a, normalized by subtraction of dilution only values. (c). Rab7 
was preincubated with BODIPY-GDP (40 nM) for 2 h 15 min at 4°C as for (a). 
Dissociation assays were initiated by dilution +/- CID1067700 (10 µM) or unlabeled 
GDP (10 µM) and decrease in fluorescence due to nucleotide dissociation was measured 
in real time. (d) Single phase exponential analysis of c, normalized by subtraction of 
dilution only values.   
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   In another approach, in the absence of excess unlabeled GTP, CID1067700 and 
BODIPY-nucleotide competitively substitute for each other at the binding site when 
direct ligand competition was assayed. BODIPY-GTP or GDP (25-200 nM) was allowed 
to bind Rab7wt protein for 100 s in the absence of DMSO or CID1067700. At the 
indicated times, either 1% DMSO or 10 µM CID1067700 (final) was added as 
fluorescent nucleotide loading was allowed to continue in real time (Arrows, Fig. 9a-b, 
9d-e). Relative to DMSO, addition of CID1067700 resulted in an immediate reduction in 
further nucleotide binding/loading. Statistical normalization of the fluorescence in the 
CID1067700 treated samples, revealed maximal competition between BODIPY-GTP and 
CID1067700 when the inhibitor was in 50-fold excess over the nucleotide (200 nm 
BODIPY-GTP vs. 10 µM) (Fig. 9c). Thus, binding of CID1067700 behaves as the rate 
limiting step in this circumstance. In contrast, BODIPY-GDP outcompetes CID1067700 
with nearly complete efficacy (Fig. 9f). 
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Figure 9: CID1067700 precludes nucleotide loading through direct displacement of 
fluorescent nucleotide. (a-c) Rab7 first incubated with BODIPY-GTP and then 1% 
DMSO final added at the point indicated by an arrow or (b) Rab7 first bound with 
BODIPY-GTP and then 10 µM of CID1067700 final added at the point indicated by an 
arrow and (c). Normalization of (b) reveals competition between BODIPY-GTP and 
CID1067700 at 200 nM concentration of the BODIPY-GTP and that binding of 
CID1067700 is the rate limiting step. (d-f) Rab7 first bound with BODIPY-GDP and then 
1% DMSO final added at the point indicated by an arrow or (e). Rab7 first bound with 
BODIPY-GDP and then 10 µM CID1067700 final added at the point indicated by an 
arrow and (f). Normalization of (e) reveals that BODIPY-GDP outcompetes CID1067700 
better than BODIPY-GTP. Comparison made with (c). 
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Nucleotide binding kinetics in the presence of CID1067700 indicates competitive 
mechanism 
   To obtain an alternative confirmation of the mechanism of CID1067700 inhibition and 
therefore binding kinetic parameters, real time on rate kinetic measurements were made 
using bead-based flow cytometry, as previously described (133). Varying the 
concentration of CID1067700 over a 10-fold range revealed that the compound saturates 
binding sites on Rab7 at 1 µM concentration (Fig. 10a and Fig. 10d).  On-rate kinetic 
measurements of BODIPY-GTP and BODIPY-GDP binding in the presence of a fixed 
concentration of CID1067700 (1 µM for maximum inhibition) or DMSO control (2 min 
pre-incubation) revealed CID1067700 decreased Rab7 BODIPY-nucleotide (GTP and 
GDP) binding over a 4-fold nucleotide concentration range (Fig. 10b-c, e-f). Statistically, 
there was no effect on the observed association rate constant (kob), a parameter that may 
reflect the affinity of nucleotide for Rab7. Kinetic analyses corroborated the equilibrium 
binding data and supported a competitive inhibition of Rab7 nucleotide binding by 
CID1067700.   
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Figure 10: CID1067700 has a fast binding equilibrium and reduces the apparent 
number of binding sites for fluorescent nucleotide on wild type Rab7. (a) Rab7wt 
was preincubated with either 1% DMSO (blue) or CID1067700 (0.1 or 1µM) for 2 min at 
4°C before addition of 100 nM BODIPY-GTP or (b-c) Rab7wt pre-incubated with either 
1% DMSO or CID1067700 (1 µM) for 2 min at 4°C before addition of  (50-200 nM) 
BODIPY-GTP. (d). Rab7wt was preincubated with either 1% DMSO (blue) or 
CID1067700 (0.1 or 1µM) for 2 min at 4°C before addition of 40 nM BODIPY-GDP. (e-
f) Rab7wt pre-incubated with either 1% DMSO or CID1067700 (1 µM) for 2 min at 4°C 
before addition of  (50-200 nM) BODIPY-GDP. Baseline fluorescence reading shown for 
first 50s after which kinetics of BODIPY-nucleotide binding was measured for 200s. 
Added nucleotide concentration ranged from 50-200 nM are color coded. 
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Molecular docking of CID1067700 on Rab7wt GDP and GTP bound crystal 
structures predicts optimal binding to the nucleotide binding pocket of the GTP-
conformer 
     The molecular docking of CID1067700 in the nucleotide binding site of Rab7 as 
predicted by the experimental data was examined using molecular docking OpenEye Fred 
docking software (Fig. 11a-h). Docking of CID1067700 on the GDP- and GTP-
conformers of Rab7 revealed that the molecule fills the nucleotide binding pocket of both 
conformers in a manner that mimics the nucleotides (Fig. 11a-d). However, the 
interaction map revealed that the compound had fewer potential interactions with GDP-
conformer where the binding pocket is more exposed to solvent, which may also explain 
why BODIPY-GDP outcompetes CID1067700 better than the BODIPY-GTP (Fig. 11e-
f).  Comparatively, the good alignment between CID1067700 and GNP where 5,7-
dihydro-4H-thieno[2,3-c]pyran ring system has the same orientation as guanine ring 
system may suggest the binding mode of the small molecule in nucleotide binding 
pocket. However, a crystal structure determination study involving both CID1067700 and 
Rab7 will be required to confirm the most likely binding mode. 
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Figure 11: CID1067700 docks optimally in the nucleotide binding pocket of Rab7 in 
the GTP-bound conformation. (a-d) CID1067700 docked in the nucleotide binding site 
of Rab7 in the (GNP)- bound (PDB 1VG8) and GDP-bound (PDB 1VG9) conformations. 
Molecular docking carried out using Fred docking software. Both GTP or GDP and 
CID1067700 are shown simultaneously docked in the pocket for purposes of comparing 
their orientations in the pocket.  
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Figure 11. (e-h) Interaction maps for Rab7-GNP vs. CID1067700 and Rab7-GDP vs. 
CID1067700 illustrate differences in number and sites of interaction. 
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Structure activity analyses identify critical determinants for competitive inhibition 
   To determine structure activity relationships (SAR), eighteen variants of the parent 
compound were evaluated.  This preliminary SAR set was obtained through synthetic 
effort (11 compounds) or commercial acquisition (7 compounds).  The parent scaffold, 
represented by CID1067700, was modified in any of three major regions to afford the 
initial analog collection.  The structural alterations focused on esterification of the 
carboxylic acid (R1), geminal substitution changes on the fused pyran ring (R2, R3), 
mutation of the ring-fused pyran to an N-methylated ring-fused piperidine, or revision of 
the N-acyl thiourea linker (L).  Only three of the compounds retained activity in a 
multiplex GTPase screen with all other derivatives being inactive (Table 2).  The parent 
and the three active derivatives were assayed in single-plex dose response assays and 
EC50 determined against Rab7 (Fig. 12a-e and Table 5). Esterification of the carboxylic 
acid moiety resulted in loss of inhibition, a finding that supports the suggested 
participation of this group in hydrogen bonding (Fig. 11).  Removal of one or both of the 
gem-dimethyl groups from the parental thiophenylpyran structure (R2-R3) resulted in a 
10- or 20-fold loss in potency, respectively.  The effect on potency observed with the 
gem dimethyl substitution suggested an advantageous lipophilic ligand-binding site 
interaction that is lost upon substituent removal.  Alteration of the N-acyl thiourea linker 
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further attenuated potency, as demonstrated by the 35-fold loss in potency observed with 
N-acyl urea CID46916265, and the complete loss of activity for thiourea CID1280844 
and amide CID740871.  While further SAR work is required to attribute specific linker 
functionality with preferred binding interactions, these preliminary results indicate that 
the orientation of tethered groups, and the length and hydrogen-bonding character of the 
linker region are critical to maintaining a beneficial activity profile. 
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Table 2: Molecular scaffolds responsible for CID1067700 inhibitory activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
R2 L
R3
OO
R1
O S
Pubchem Pubchem RR R L
2
*
EC ( M)Entry
SID CID
21 3 50
57578339 1067700 H Me Me C2 N
H
N
H
S O
*
0.0241
99381128 46916263 H Me C2 N
H
N
H
S O
*
0.272 H
S O
99381129 46916266 H C2 N
H
N
H *
0.503 HH
C2 N N
S O
> X (limits99361118 1251121 Me H H * of assay)4 MeMe
99381130 46916265 H
C2 N
H
N
H
O O
* 0.835 MeMe
99381127 1280844 H
C2 N
H
N
H
S
*6 MeMe > X (limitsof assay)
99381117 740871 H
C2 N
H
O
*7 MeMe > X (limitsof assay)
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Figure 12: Structure activity relationships identify importance of linker and R-
groups in inhibitory activity of CID1067700. (a). Fig. 1 (d) included for comparison 
with derivatives of CID1067700. (b) Nanomolar concentrations of CID46916263 
derivative with only single methyl replacement on the pyran group and intact 
carbamothioylamino linker inhibit Rab7wt protein nucleotide binding; BODIPY-GTP 
(100 nM, filled squares) and BODIPY-GDP (40 nM, filled triangles). (c) Nanomolar 
concentrations of CID46916266 derivative with only two methyl replacement on the 
pyran group and intact carbamothioylamino linker inhibit Rab7wt protein nucleotide 
binding; BODIPY-GTP (100 nM, filled squares) and BODIPY-GDP (40 nM, filled 
triangles).  
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Figure 12. (d) Nanomolar concentrations of CID46916265 derivative with only 
alteration of the thiourea moiety of the carbamothioylamino linker inhibit Rab7wt protein 
nucleotide binding; BODIPY-GTP (100 nM, filled squares) and BODIPY-GDP (40 nM, 
filled triangles). (e) Nanomolar concentrations of CID1251121 derivative with alteration 
of the carboxylic acid group only do not show any activity towards inhibition of 
nucleotide binding by Rab7wt protein.  
 
 70 
Discussion and conclusion 
   In this chapter, a small molecule (CID1067700) identified from high throughput 
screening has been shown to inhibit nucleotide binding by Rab7 in the nanomolar range 
with EC50 values of 25 nM for BODIPY-GTP and 40 nM for BODIPY-GDP plus 
calculated efficacy of nucleotide binding inhibition of 60% for BODIPY-GDP and 80% 
for BODIPY-GTP. Kinetic and equilibrium binding studies demonstrate that the 
compound acts as a competitive inhibitor and exhibits a good fit to the nucleotide binding 
pockets of both the GTP- and GDP-bound conformations of Rab7. By assaying rate 
kinetics of Rab7 nucleotide binding in the presence of CID1067700, we noted a decrease 
in the number of BODIPY-GTP and BODIPY-GDP binding sites on Rab7 across the 
entire nucleotide concentration range considered. Based on equilibrium dissociation 
measurements, we also showed that CID1067700 does not affect how fast or slow Rab7 
releases bound nucleotide suggesting that CID1067700 inhibits Rab7 nucleotide binding 
through a competitive mechanism.  
   Initial structure activity relationships demonstrate a dependence on the lipophilic 
interactions with the substituted ring-fused pyran, the hydrogen bonding capability of the 
carboxylic acid, and the integrity of an extended N-acyl thiourea linker to properly extend 
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and orient the tethered aryl functionality. Although our assays have focused on 
characterizing the small molecule on Rab7, CID1067700 also exhibits inhibitory activity 
on other small GTPases (Fig. 6c). To the best of our knowledge CID1067700 is the first 
example of a competitive inhibitor for small GTPases. CID1067700 was found to also 
inhibit nucleotide binding by both the Rab7Q67L and Rab7T22N mutants that are known 
to be constitutively in the GTP and GDP bound states, respectively (30). Although the 
Q67L mutation lies in the nucleotide binding pocket of Rab7, the actual location of the 
Gln67 residue in the pocket is remote from all predicted contacts with CID1067700. 
From analysis of the crystal structure Thr22 residue is involved in forming interactions 
with Mg+2 cofactor which is required for GTP/GDP binding, and although CID1067700 
small molecule inhibitor has a similar binding mode to nucleotides, molecular docking 
studies suggest that magnesium cofactor may not be essential for its binding. Another 
important question that the current findings raise is about the conformational state Rab7 
may adopt once bound to CID1067700. This question is significance because Rab7 
downstream function in cells is entirely dependent on its active (GTP-bound) state. To 
address this question, an in vitro effector protein binding assay was carried out and 
demonstrated that when Rab7 is bound to CID1067700, Rab7 is not able to bind its Rab 
interacting lysosomal protein (RILP) effector (Appendix C). This suggests that when 
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CID1067700 binds Rab7 the complex mimics the inactive GDP conformational state. 
This finding is in agreement with data that in cells incubated CID106770 epidermal 
growth factor receptor downregulation is impaired, consistent with inhibition of Rab7 
function (Hong, Basuray, Sklar and Wandinger-Ness, unpublished observation).  
Implications and significance of CID1067700 functional inhibition of Rab7  
   The identification of CID1067700 as a competitive inhibitor of Rab7 nucleotide 
binding presents an exciting and novel route to characterize Rab family proteins. Most 
small molecules reported to be active against low molecular GTPases are allosteric 
inhibitors and have activities that are restricted to the Rho-family GTPases based on their 
mechanism of action of blocking GEF interactions with Cdc42, Rac1 and RhoA (138). 
Thus, the identification of CID1067700 together with analyses of structure activity 
relationships suggest that it may be possible with further development to prepare more 
specific analogs with unique advantages when compared to traditional approaches of 
studying cell physiology such as conditional knock out or RNA interference as a means 
to perturb Rab GTPase functionality. Small molecules also can be applied to cells to 
rapidly and often reversibly inhibit targets. This is exemplified by Brefeldin A, an 
allosteric inhibitor of Arf GTPases (13) and inhibitors of phosphoinositide 3-kinases that 
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have been shown to inhibit specific kinase isoforms (139, 140). Moreover, Rab7 function 
depends on numerous protein-protein interaction partners including hVps39 (141), 
TBC1D15 (109, 142), RILP (36, 129, 143), ORPIL (65, 78), Rabring7 (83, 84) and the 
alpha proteasome subunit XAPC7 (71, 82) whose interaction with Rab7 may be potential 
candidates for small molecule modulation. A small molecule might also be useful for 
dissecting the order of protein binding to a multimeric complex and/or the importance of 
nucleotide for stability of the protein complex involving Rab7. Taken together, our 
findings present CID1067700 as a novel competitive inhibitor of small GTPase 
nucleotide binding that has potential for dissecting protein function in vitro. It may serve 
as a springboard for further development of families of compounds selective for 
individual GTPases like members of the Rho family of GTPases. 
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CHAPTER THREE 
FUNCTIONAL CHARACTERIZATION OF RAC1 USING 
R-NAPROXEN ISOFORM 
Abstract 
    Abnormal function of Rho family GTPases has been associated with human tumors of 
the colon, breast, lung, head and neck. Because of their roles in cell adhesion and 
migration, Rho family GTPases have been suggested as potential therapeutic targets in 
human cancers. In collaborative studies, Rac1 is identified as over expressed in human 
ovarian cancer and thus a novel target.  Inhibition of Rac1 GTPase function by the R-
Naproxen isoform is demonstrated, and shown to be distinct from the commercially 
marketed S-Naproxen.  R-Naproxen was initially identified by flow cytometry based high 
throughput screening of the Prestwick compound library as a select non-steroidal anti-
inflammatory drug (NSAID) that targets Rac1. R-Naproxen inhibits EGF-stimulated 
Rac1 activation as well as altering sub-cellular localization of Rac1 and its guanine 
nucleotide exchange factor (GEF), Tiam1 at physiologically relevant doses.  In vitro 
assays show that R-Naproxen does not inhibit Rac1 interaction with its Tiam1 guanine 
exchange factor (GEF). Molecular docking predicts that R-Naproxen can favorably bind 
the nucleotide pocket of the GDP-bound Rac1, but not the GTP-bound Rac1, suggesting 
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potential inhibition through stabilization of the inactive protein. Taken together, the 
findings present R-Naproxen as a potential therapeutic molecule for further consideration 
in metastatic ovarian cancer research. 
Introduction 
    Like the Rab family, Rho GTPases play important and diverse roles that ensure normal 
cellular physiology.  Ten different mammalian Rho GTPases, some with multiple 
isoforms; Rho (A, B, C isoforms), Rac (1, 2, 3 isoforms), Cdc42 (Cdc42Hs, G25K 
isoforms), Rnd1\Rho6, Rnd2\Rho7, Rnd3\ RhoE, RhoD, RhoG, TC10 and TTF have 
been identified to date (144). Rho, Rac and Cdc42 GTPases are the most characterized 
members though more research continues to accumulate in this area. Currently, about 22 
genes encoding different members of the Rho family have been identified in the human 
genome (145).  
Functional role of Rac1 
    The primary role of Rho GTPases is centered on the assembly and organization of the 
actin cytoskeleton. In response to extracellular cues, activation of Rho, Rac, or Cdc42 
small GTPase leads to the assembly of contractile actin:myosin filaments, protrusive 
actin-rich lamellipodia, and protrusive actin-rich filopodia, respectively (146-150). The 
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effects on the actin cytoskeleton suggest well coordinated signal transduction pathways 
controlled by each GTPase leading to both the formation (actin polymerization) and the 
organization (filament bundling) of actin filaments. The integrity of the cytoskeletal 
network influences processes such as cytokinesis(151-153), phagocytosis (154, 155), 
pinocytosis (148), cell migration (156, 157), morphogenesis (158) and axon guidance 
(159). These processes are highly impacted in various disease conditions like cancer. A 
member of the Rho family of GTPases particularly associated with coordination of cell 
proliferation, adhesion, and migration/invasion is Rac1. Among the Rac isoforms, Rac1 
is ubiquitously expressed, Rac2 is a hematopoietic lineage-specific GTPase regulating 
superoxide generation via the NADPH oxidase in phagocytes, and Rac3 is expressed 
primarily in the brain (160-163). 
     The role of Rac1 in cell proliferation has been demonstrated through several findings. 
In cholangiocarcinomas cells, it was shown that blocking Rac1 using siRNA significantly 
suppressed cell proliferation and induced apoptosis (164). In another study, knock down 
of Rac1 using siRNA was found to impair proliferation of bovine aortic endothelial cells 
(165). In MDA-MB-231 cells, blocking of Rac1 using NSC23766, a small molecule 
which inhibits Rac1 interaction with its Tiam1 GEF, was reported to induce G1 cell cycle 
arrest and prevent cell proliferation (138). Rac1 activation is also associated with 
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cadherin-mediated cell-cell adhesion (166). This was demonstrated in normal human 
keratinocytes where expression of dominant negative N17Rac1 was found to inhibit E-
Cadherin mediated cell-cell adhesion (167).  
    Cell migration plays a central role in processes such as embryonic development, 
wound repair, inflammatory response and tumor metastasis. The migrating cell requires 
actin-dependent protrusions at the front and contractile actin:myosin filaments at the rear 
besides stabilization of microtubules originating from the centrosome in the direction of 
migration (168-170). These actin based structures are to enhance targeted vesicle 
trafficking from the Golgi apparatus to the leading edge. Rac1 functioning in concert with 
WAVE and Arp2/3 promotes cell migration at the leading edge where it induces the 
formation of actin-rich lamellipodia protrusions, serving as the major driving force of cell 
motility (156, 171-174). In chemotaxing neutrophils, accumulation of Rac1 at the leading 
edge is aided by PI(3)-kinase and its product, phosphatidylinositol 3-phosphate (PI3P) 
(175). In neutrophil models, it has been shown that the polarized accumulation of PIP3 is 
aided by localization of the lipid phosphatase PTEN to the sides and rear of the migrating 
cell (176, 177). In addition to WAVE and Arp2/3 proteins in cell migration, the 
functional role of Rac1 in cell migration is also dependent on other interacting effector 
proteins. For example; DOCK180 which despite lacking requisite DbI homology-
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pleckstrin homology (DH-PH) tandem domain, regulates GDP-GTP exchange of Rac and 
facilitates its cell migration role (178, 179).  
     In disease conditions such as cancer, processes of cell proliferation, adhesion, and 
migration are key determinants of disease severity. More often the lethality of cancer is 
heavily influenced by how far the tumor cell has spread from the point of origin. This 
situation thus makes therapeutic targeting of Rac1 as well as Rac1 driven migratory 
processes a tractable strategy. As alluded to above, whether under physiologically normal 
conditions or in disease states, all Rac1 associated functions do not occur in isolation but 
rather depend on their interaction with regulatory effector molecules. 
Regulation of Rac1 
    Like the Rabs, Rho GTPases also undergo prenylation prior to membrane recruitment 
(146). They equally cycle between an active GTP-bound state and an inactive GDP-
bound state (Fig. 1). This transition is similarly controlled by (a) Rho guanine nucleotide 
exchange factors (GEFs) (180); (b) Rho GTPase- activating proteins (GAPs) (181); and 
(c) Rho guanine nucleotide dissociation inhibitors (GDIs), that block spontaneous 
activation (182). Many Rho GEFs were originally identified as oncogenes after 
transfection of immortalized fibroblast cell lines with cDNA expression libraries (183).  
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Characteristically, nearly all Rho GEFs share DH (Dbl homology) domain adjacent to a 
PH (pleckstrin homology) domain features.  Notable among the Rho GEFs is the T-cell 
invasion and metastasis 1 (Tiam1) protein. Tiam1 was originally identified in a retroviral 
insertional mutagenesis screen of murine T-lymphoma cells (184). Tiam1 possesses the 
characteristic Dbl homology (DH)–pleckstrin homology (PH) domain combination and is 
widely expressed (185). The Tiam1 protein consists of two N-terminal PEST domains, an 
N-terminal PH domain (PHn), a coiled-coil region with adjacent sequence (named CC-
ex) (186, 187), a Ras-binding domain (RBD) (188), a PSD-95/DlgA/ZO-1 domain and 
the characteristic catalytic DH–PH (named PHc) combination.   
     In the cell, Tiam1 is primarily localized on the membranes, an environment found to 
be crucial to its induction of Rac-mediated membrane ruffles and activation of c-Jun N-
terminal kinase  (187). While the presence of a lipid domain is key to Tiam1 GEF 
activity, phosphorylation is another event that may directly trigger its membrane 
translocation and/or GEF activity. Tiam1 is reported to be phosphorylated on threonine 
residues by Ca2+/calmodulin kinase II (CaMK-II) and protein kinase C (PKC) in vitro and 
upon treatment of Swiss 3T3 fibroblasts with lysophosphatidic acid (LPA) and PDGF in 
vivo (189-191). Thanks to virtual screening and rationale design, the small molecule 
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NSC23766 was identified and confirmed as an inhibitor of Rac1 interaction with Tiam1 
(138). 
     Like the GEFs, a large number of Rho GTPase family GAPs have been identified to 
date (181). For the case of Rac1, β2-chimaerin, ArhGAP1, and YopE have been 
identified to possess GAP activity (192-194). As opposed to YopE, which possesses GAP 
activity towards Rac1, Rho and Cdc42 (193), β2-chimaerin GAP activity was shown to 
be phospholipid dependent and more specific towards Rac1 than Rho and Cdc42 (194). 
In both Rab7 and Rac1 GTPases, the regulatory process involving GEFs, GAPs and 
effector molecules is conceptually analogous to an electronic circuit system in which 
GEFs act as electronic signal amplifiers, while GAPs that inactivate the GTPase present 
as signal attenuators. Effector molecules that couple GTP bound (active) GTPase proteins 
with downstream signaling events are analogous to electronic signal integrators. Granted 
the dependence of Rab or Rho GTPase function on partner molecules, careful elucidation 
of both regulatory factors and effectors is crucial for effective implementation of 
therapeutic strategies taking into consideration the need to avoid pathways with 
functional redundancies. 
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Association of Rac1 GTPase with human disease:  Rac1 and cancer 
    Mounting evidence has linked Rho GTPases with cancer development (Appendix D) 
(195-198). Abnormal function of Rho GTPases has been associated with human tumors 
of the colon, breast, lung, head and neck, and ovary (199-203). A member of the Rho 
GTPases widely expressed in several human cancers is Rac GTPase (204-206). Its role in 
cell migration is a key determinant of tumor cell metastasis (Fig. 13).  
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Figure 13: Rho family of GTPases in tumor metastasis. Rac1 is involved in processes 
leading to loss of cell polarity, loss of cell-cell junctions and cell motility. Rho like Rac1, 
regulates processes that coordinate loss of cell polarity and multilayering, loss of cell-cell 
junctions and cell motility. These are characterized by formation of stress fibers and focal 
adhesion that in turn ensure both amoeboid and mesenchymal migration. Cdc42 is 
associated with processes that establish normal cell polarity as well as migratory polarity 
with the latter marked by protrusive actin-rich filopodia at the leading edge of the cell.   
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     The role played by Rac1 GTPase in cancer pathogenesis has been well documented. In 
proliferating epithelial breast cells and breast cancer, Rac1 protein was found to be highly 
expressed and to be linked to metastasis of these cells (207). In the same vein, in a breast 
cancer cell line, inhibition of Rac1 using Rac inhibitor EHT1864 down-regulated ERα 
expression and breast cancer cell proliferation (208). ERα plays a critical role in the 
pathogenesis of the breast cancer disease (209-211). Another group showed that Rac1 is 
critically involved in non-small cell lung adenocarcinoma (NSCLA) cell migration, 
invasion and lung metastasis of SP cells (212) which echoed previous research linking 
tumorigenesis in LSL-K-rasG12D mouse model of lung adenocarcinoma with the 
expression levels of Rac1 (213).  
      In many colorectal cancers, Rac1 or the Rac1 specific GEF (Tiam1) is over expressed 
(214-216). Tiam1 in colorectal cancers is a transcriptional regulator of the canonical Wnt 
signalling pathway (215, 217). The synergy of Rac1 and Tiam1 expression levels in 
colorectal cancers correlate with the findings that showed that an interplay of Rac1 and 
Tiam1 modulates Wnt target gene transcription by associating with the β-catenin/TCF 
transcription factor complex at Wnt-responsive promoters (218). Dysregulation in Wnt 
signaling is associated with the development of many cancers including colorectal cancer 
(219). The role of Rac1in some cancers sometimes may depend on a more complicated 
 84 
pathway. For example, in SKOV3 ovarian cancer cell line, the Rac1 role in cancer 
development was found to be dependent on the Crk/Dock180/Rac1 pathway (220) and 
important in ovarian cancer cell proliferation, motility and invasion (220). 
     Ovarian cancer occurs with high prevalence, killing about 20,000 women annually 
(221, 222). Most cases of ovarian cancer are diagnosed when the cancer has already 
spread, leading to 5-year survival rate of less than 40 % (222). The main reasons behind 
this poor prognosis are: (i) lack of understanding of the molecular underpinnings of the 
disease and (ii) predominant localization of ovarian cancer cells within the peritoneal 
region which complicates early diagnosis (222). At the molecular level, one strategy for 
addressing the ovarian cancer problem is through targeting a protein that is directly 
associated with cancer cell metastasis such as Rac1 GTPase. This strategy is not only 
vital in the context of having a grasp of the ovarian cancer disease etiology but also may 
present Rac1 as a potential therapeutic target in ovarian cancer disease.  
    For many years, dominant negative mutants of Rac have been the preferred choice in 
studying Rac function in cells. However, given the difficulty of introducing high 
concentrations of the Rac mutants into primary cells coupled with non-specific effects of 
the mutants on effector molecules such as Rho guanine nucleotide exchange factor (GEF) 
 85 
activities, it has become desirable to explore the use of small molecules to target Rac 
activities. Different strategies have been applied for this purpose. In one approach small 
molecules to modulate Rac1 nucleotide binding and therefore interfere with downstream 
events linked to Rac1 activation have been developed. One such inhibitor is EHT1864 
(223).  Functionally, EHT1864 inhibits Rac family GTPases by placing Rac1 in an inert 
and inactive state (guanine nucleotide displacement mechanism) and thus impairing 
Rac1-mediated functions in vivo (223).  The second approach involves small molecule 
interference of Rac1 protein-protein interactions with the best characterized one being 
NSC23766 specific inhibition of Rac1-Tiam1 interaction (14, 14, 138, 224-226).  
    A strategy for targeting Rac1 protein function through non-steroidal anti-inflammatory 
drugs (NSAIDs) has established by the Wandinger-Ness lab in collaboration with 
Hudson, Sklar and colleagues. NSAIDs are commonly used for pain management and 
best known for their inhibitory activity on cyclooxygenase enzymes. Preliminary data 
accumulated from high throughput screening (HTS) performed by the UNM Center for 
Molecular Discovery suggested that Rac1 may be functionally regulated by NSAIDs 
(unpublished). The limited, documented studies on the use of NSAIDs to manage human 
cancer have tended to be mainly epidemiological with little thrust on the molecular basis 
of the disease (227-229), which may provide beneficial effects in terms of cancer stage 
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and age of onset. It was therefore the aim of the dissertation work to elucidate how the 
NSAID drug, Naproxen, may regulate Rac1 protein function in an ovarian cancer cell 
line.  
     Naproxen comes in two isomeric forms, R-isomer and S-isomer (Fig. 14). Both have 
the same chemical formula but different conformations in space at the chiral center (230). 
The two different conformations can induce different chemical behaviors between the 
two isomeric forms that will be shown in the results section. This is in line with the 
increasing experimental evidence showing that chiral NSAIDs inhibit both COX-2 and 
COX-1 isoenzymes with comparable stereoselectivity (231, 232).  For instance, in an in 
vitro system of guinea pig whole blood, lipopolysaccharide (LPS)-stimulated human 
monocytes, and purified preparations of COX-2 from sheep placenta, S-enantiomers of 
ketoprofen, flurbiprofen, and ketorolac were found to display exclusive inhibitory effect 
on COX-2 enzyme as opposed to COX-1 (232). In cancer studies as well, R-etodolac was 
shown to be better at inducing apoptosis of prostate cancer cells than the S-etodolac 
(233). In this study, we provide evidence that the R-enantiomer of Naproxen as opposed 
to the S-enantiomer functionally inhibited Rac1 and its associated downstream cellular 
processes in ovarian cancer cell lines. A related NSAID, 6-methoxy-2-napthalene acetic 
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acid (6-MNA) compound (Fig. 14) which is structurally very similar to Naproxen but 
lacks chiral center was used as a negative control. 
 
 
 
 
 
 
 
 
 
 
Figure 14: Molecular structures of the NSAID compounds used in the study 
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Materials and Methods  
Reagents 
    Reagents used in this part of the study were obtained from different sources as 
indicated. G-LISATM Rac Activation Assay kit  (Cytoskeleton, Denver, CO, USA), 
RhoGEF exchange assay kit (Cytoskeleton, Denver, CO, USA), DMEM and MEM media  
(Invitrogen, Carlsbad, CA, USA) and c-Myc Tag IP/Co-IP Kit  (Thermo Fisher 
Scientific, Rockford, IL, USA). R-Naproxen, S-Naproxen and 6-methoxy-2-napthalene 
acetic acid (6-MNA) were obtained from the chemical library of off patent drugs 
(Prestwick, Washington DC, USA), Sigma-Aldrich (St. Louis, MO, USA) and Cayman 
Chemical (Ann Arbor, MI, USA), respectively. 
Rac1 activation assay in the presence of Naproxen 
    The Rac1 activation assay was carried out using G-LISATM Rac Activation Assay kit 
procedures (Cytoskeleton, Denver, CO, USA). The principle of the assay is based on the 
interaction of active Rac (Rac-GTP) with its p21-kinase (PAK1) effector. The bound 
active Rac is detected with a Rac specific antibody. The extent of Rac activation is based 
on the absorbance readings (read at 490 nm) between the activated cell lysates versus 
non-activated cell lysates. The assay was carried out in Swiss 3T3 fibroblast and 
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OVCA433 cell lines. Swiss 3T3 cells are known to a show robust Rac1 activation upon 
EGF stimulation and were therefore used for baseline kinetic measurements. The Swiss 
3T3 cells were cultured in DMEM media (DMEM, L-glutamine, Penicillin/Streptomycin 
antibiotic and fetal calf serum) and then subjected to a two-step starvation by sequentially 
scaling down the concentration of fetal calf serum (FCS).  The OVCA433 cells were first 
cultured in MEM media (MEM, L-glutamine, Penicillin/Streptomycin 
 antibiotic and 10% fetal calf serum) for 24 h and then starved for 24 h in the culture 
media containing 0.1 % bovine serum albumin (BSA). A time course of EGF-dependent 
Rac1 activation was first carried out in both cell lines without any small molecule. This 
established 2 min of EGF stimulation for maximal Rac1 activation.  
     In the presence of small molecule, the starved OVCA433 cells were appropriately 
treated for 1 hour with R-Naproxen (300 µM final), S-Naproxen (300 µM final), and 6-
MNA (300 µM final) dissolved in aqueous buffer system. To enhance the dissolution of 
R-Naproxen and 6-MNA in aqueous buffers, the pH of the solution had to be adjusted to 
at least 8.0 using 40 mM Tris-Base while S-Naproxen was dissolved in double distilled 
water. One set of treated cells was then stimulated with EGF (10 ng/ml final) for 2 
minutes before harvesting and storing the cell lysate as per prescriptions of the G-LISATM 
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Rac Activation Assay kit. The starved Swiss 3T3 cells were subjected to a time 
dependent treatment with R-Naproxen and 6-MNA before stimulation with EGF  (10 
ng/ml) for 2 minutes. Harvesting and storage followed the same procedure as for the 
OVCA433 cells. 
Rac1 guanine exchange factor (GEF) assay in the presence of Naproxen 
    The Rac1 GEF assay was carried out according to the protocol outlined in the RhoGEF 
exchange assay kit, BK100 (Cytoskeleton, Denver, CO, USA). Immunoprecipitated myc-
tagged Tiam1 was used in the assay for GEF activity. HeLa cells were cultured for 
transfection using standard cell culture procedures. At 80% confluency, the cells were 
transfected with myc-Tiam1 plasmid using LipofectamineTM 2000. The cell lysate was 
harvested according to procedures stipulated in the c-myc tag IP/co-IP kit (Thermo 
Scientific, Pierce Biotechnology, Rockford USA) and then stored at -80oC. To carry out 
the Rac1 GEF assay in the presence of small molecule, the following procedure was 
adopted. Phosphatidylinositol 4,5-bisphosphate (PIP2) lipid in CHCl3: MeOH:H2O 
mixture was dried under vacuum and then redispersed in immunoprecipitation elution 
buffer (50 µl) using intermittent bath sonication and vortexing.  The equivalent of 10 µM 
of PIP2 lipid (final) was incubated with 1 µM Myc-Tiam1 (full length) solution for 5 
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minutes at room temperature as reported earlier (234) and then put on ice. His-Rac1 (45 
µM final) constituted in sterile water was mixed with nucleotide exchange buffer (20 mM 
Tris-HCl pH = 7.5, 50 mM NaCl, 10 mM MgCl2, 5 % BSA and 0.75 µM Mant-GTP) in a 
100 µl volume (final) in a light sensitive 96 well plate. 1 % DMSO (final), 100 µM R-
Naproxen in 1 % DMSO  (final) and 100 µM 6-MNA in 1 % DMSO (final) were then 
added accordingly. The mixture was briefly shaken on a bench top shaker for 30 sec 
before further incubation for 5 minutes at room temperature. Initial fluorescence 
measurements were obtained for 5 minutes on the fluorimeter plate reader (1420 
Multichannel counter, PerkinElmer) by exciting mant-GTP at 360 nm and recording 
emitted fluorescence at 440 nm. PIP2 lipid bound Myc-Tiam1 (10 µM final) was then 
added to appropriate wells and fluorescence changes monitored. Control wells in the 
assay consisted of Rac1 treated with H2O only and 1% DMSO. PIP2 served as a Tiam1 
GEF activator in the assay by binding lipid homology domains of Tiam1 (234). 
Molecular docking of R-Naproxen on Rac1 
    Docking calculations were performed using OpenEye Fred (Fred, version 2.2.5, 
OpenEye Scientific Software, Inc., Santa Fe, NM, USA, www.eyesopen.com, 2010) 
docking software. Rac1 crystal structure (PDB code: 1I4D) was used to dock R-
Naproxen on Rac1 wild type crystal structure. Chemgauss3 scoring function was used to 
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evaluate ligand binding potential. Docking simulations provide only a qualitative 
assessment of binding probability of R-Naproxen ligand to Rac1 and should be examined 
with care.  
R-Naproxen inhibition of COX enzymes relative to S-Naproxen  
    The R-Naproxen inhibitory effect on COX enzymes relative to S-Naproxen was 
assayed by a contracted commercial company (CEREP, Seattle, USA). The following 
procedures obtained from CEREP were used. For COX-1, the test compound, reference 
compound or water (control) were first pre-incubated for 20 min at 22°C with the enzyme 
(≈ 5 µg) in a buffer containing 90 mM Tris-HCl (pH 8.0), 2 mM phenol and 1 µM 
hematine. Thereafter, the reaction was initiated by adding 4 µM arachidonic acid and the 
mixture incubated for 5 min at 22°C. Following incubation, the reaction was stopped by 
the addition of 1 M HCl then 1 M Tris/HCl (pH 8.0) followed by cooling to 4°C.  For 
basal control measurements, arachidonic acid was omitted from the reaction mixture.  
    The fluorescence acceptor (D2-labeled PGE2) and the fluorescence donor (anti-PGE2 
antibody labeled with europium cryptate) were then added. After 120 min, the 
fluorescence transfer was measured at λex=337 nm, λem=620 and λem=665 nm using a 
microplate reader (EnVision, Perkin Elmer). The enzyme activity was determined by 
dividing the signal measured at 665 nm by that measured at 620 nm (ratio). The results 
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were finally expressed as a percent inhibition of the control enzyme activity. The 
standard inhibitory reference compound was diclofenac, which was tested in each 
experiment at several concentrations to obtain an inhibition curve from which its IC50 
value was calculated.  
     On the other hand, the approach followed to assay inhibition of COX-2 enzyme was 
slightly different from that used for COX-1. The test compound, reference compound or 
water (control) were pre-incubated for 20 min at 22°C with the enzyme (≈ 0.2 µg) in a 
buffer containing 90 mM Tris-HCl (pH 8.0), 2 mM phenol and 1 µM hematine. 
Thereafter, the reaction was initiated by addition of 2 µM arachidonic acid and the 
mixture was incubated for 5 min at 22°C. For basal control measurements, arachidonic 
acid was also omitted from the medium.  Following incubation, the reaction was similarly 
stopped by the addition of 1 M HCl then 1 M Tris/HCl (pH 8.0) followed by cooling to 
4°C. Fluorescence acquisition and calculation of percent inhibition were then carried out 
in the same way as in the COX-1 assay. Unlike in the case of COX-1, they used NS398 
as the standard inhibitory reference compound.  
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Results 
R-Naproxen inhibits Rac1 GTPase in ovarian (OVCA433) and Swiss 3T3 cell lines 
    As discussed previously, Rac1 plays a critical role in several aspects of tumorigenesis, 
cancer progression, invasion, and metastasis. Rac proteins are overactive or over-
expressed but not mutated in most invasive human cancers. In this study, isomeric R-
Naproxen was used to characterize Rac1 function in ovarian cancer  (OVCA433) and 
Swiss 3T3 fibroblast cell lines with and without EGF stimulation. This quantitative assay 
takes advantage of the interaction between activated Rac1 (Rac1-GTP) and GST tagged 
p21-activated kinase (PAK1) effector mobilized on a well. PAK1 is one of the six 
members of the family of serine/threonine protein kinases functioning as an effector of 
Rho GTPases (235). PAK1 controls the dynamics of cell motility by linking a variety of 
extracellular signals to changes in actin cytoskeleton organization, cell shape, and 
adhesion dynamics besides modulating cell division, apoptosis, and gene transcription 
processes (236). PAK1 pull down depends on Rac1 being in the GTP-bound state.  
     To obtain the optimum time point where maximum Rac1 activation occurs, the two 
cell lines used in the study were first subjected to time dependent EGF stimulation. The 
premise is that prior to EGF stimulation, serum starvation of the cells keeps Rac1 GTPase 
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predominantly in the GDP state (in the cytosol) such that EGF stimulation triggers a 
cascade of events that activate Rac1 and convert it to the GTP-bound state.  As shown in 
Fig. 15a-b, both OVCA433 and Swiss 3T3 fibroblast cell lines showed maximum EGF 
dependent Rac stimulation after 2 min of treatment. Swiss 3T3 cells were included in the 
study not only to elucidate R-Naproxen effect on Rac1 in a non-cancerous cell line but 
also due to its robust response to EGF stimulation.  Pretreatment of Swiss 3T3 cells with 
R-Naproxen yielded a time dependent inhibition of EGF-dependent Rac1 activation, with 
maximal inhibition after 1 h of drug pretreatment (Fig. 15c). While the 1 hr R-Naproxen 
treatment of Swiss 3T3 cells reduced EGF stimulated Rac1 activation to a level 
comparable to the serum starved basal level of Rac-GTP, treatment with 6-MNA 
followed by EGF stimulation showed modest and statistically insignificant inhibition of 
Rac1 activation. Time dependent inhibition of Rac1 by R-Naproxen suggests that Rac1 
may be a direct target of R-Naproxen in Swiss 3T3 cells. OVCA433 cells were treated 
with a fixed therapeutically relevant concentration of R-Naproxen, S-Naproxen and 6-
MNA (300 µM) for 1 hour before stimulating cells with EGF for 2 min. R-Naproxen 
blocked EGF-mediated activation of Rac1 relative to S-Naproxen and 6-MNA treated 
sets (Fig. 15d).  Given that the assay measures levels of Rac1-GTP, the results obtained 
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show that R-Naproxen, but less so S-Naproxen, acts as an inhibitor of Rac1 activation in 
cell based assays.  
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Figure 15: R-Naproxen blocks epidermal growth factor mediated Rac1 activation in 
OVCA433 and Swiss 3T3 cells. (a) Time course of epidermal growth factor mediated 
Rac1 activation in Swiss 3T3 cells. (b). Time course of epidermal growth factor mediated 
Rac1 activation in OVCA433 cells. (c). 300 µM R-Naproxen pretreatment blocks 
epidermal growth factor mediated Rac1 activation in Swiss 3T3 cells in a time dependent 
way. (d). 300 µM R-Naproxen blocks epidermal growth factor mediated Rac1 activation 
in OVCA433 cells after 1 h treatment. Both OVCA433 and Swiss 3T3 cells stimulated 
with EGF for 2 min during drug treatment. 
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    As an independent measure of Rac1 activation status in the presence of R-Naproxen 
treatment, the active Rac1 membrane bound pool and the overall protein levels of Rac1 
were measured by a combination of immunofluorescence and Western blot analyses. 
Findings are shown in Fig. 16a-c. R-Naproxen reduced the membrane bound pools of 
Rac1 (Fig. 16a) and its Tiam1 GEF (Fig. 16b) without affecting overall protein levels of 
Rac1 (Fig. 16c), in agreement with the Rac1 GLISA data. Compared to R-Naproxen, 
treatment of OVCA433 cells with the NSAIDs of Aspirin, Ibuprofen, Fenoprofen and 
Ketoprofen did not cause appreciable/significant redistribution of Rac1 from the plasma 
membrane to the cytosol (Appendix E). In a wider context, inhibition of Rac1 is 
predicted to impair actin based processes of cell proliferation, adhesion and migration. 
Dr. Laurie Hudson (collaborator in the project) and colleagues measured the effects of R-
Naproxen on ovarian cancer cell proliferation, adhesion and migration and determined 
that, R-Naproxen inhibited all the three actin based processes, a finding which correlated 
with inhibition of Rac1 GTPase activation. Studies conducted on OVCA429 cells by an 
undergraduate student in the laboratory, Anna Vestling, also showed that R-Naproxen but 
not 6-MNA, inhibited formation of protrusive actin-rich lamellipodia, and protrusive 
actin-rich filopodia (unpublished), which correlated with inhibition of Rac1 and Cdc42 
GTPases respectively.  
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Figure 16: R-Naproxen blocks membrane localization of Rac1 and Tiam1 in 
OVCA433 cells. (a) Rac1 redistributes from the plasma membrane in the presence of 300 
µM of R-Naproxen. (b). Quantification of fluorescence intensity from immunostaining of 
Rac1 in OVCA433 cells. (c). R-Naproxen does not affect overall protein levels of Rac1 
in OVCA433 cells. The cells were treated for 1 hr with R-Naproxen or indicated NSAID. 
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    Based on these results, first, we hypothesized that R-Naproxen could be interfering 
with interaction of Rac1 with its regulatory proteins such as GEFs and if that held, it 
would qualify R-Naproxen as an allosteric inhibitor in a cellular context (138, 237-239). 
Second, we hypothesized that R-Naproxen might be stabilizing Rac1 in a GDP-bound 
(inactive) state in a non-competitive fashion. Both cases can technically lead to less 
Rac1-GTP and interfere with downstream effector activation and actin remodeling 
required for proliferation, migration and invasion. To address these hypotheses, an in 
vitro qualitative assay was established to directly test the effect of R-Naproxen on Rac1 
interaction with Tiam1 GEF. 
R-Naproxen small molecule does not interfere with Tiam1 GEF activity on Rac1 
under in vitro conditions. 
     A Tiam1 GEF-Rac activation assay is described in the methods section. Myc-Tiam1 
protein was purified by immunoprecipiation for use in the assay.  Tiam1 was first shown 
to be active as a Rac1 GEF in the presence of the phosphatidylinositol 4,5-bisphosphate 
lipid activator +/- 1% DMSO (Fig. 17a). DMSO did not interfere with Tiam1 driven GEF 
response (Fig. 17a). His-Rac1 was treated with 100 µM of R-Naproxen or 6-MNA and 
assayed for mant-GTP binding in the presence of Tiam1 GEF. Contrary to the first 
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hypothesis, no inhibition of Tiam1 mediated guanine nucleotide exchange by Rac1 was 
observed in the presence of either R-Naproxen or 6-MNA (Fig. 17b-c) suggesting that R-
Naproxen may not be binding the switch regions of Rac1. R-Naproxen could be 
inhibiting Rac1 in the cell lines assayed via a different mechanism yet to be elucidated. 
This then prompted us to assess if molecular docking prediction could yield a clue on the 
most probable binding site of R-Naproxen on Rac1 and if so, that may be used as a guide 
for designing future alternative experimental approaches to assay the mechanism of R-
Naproxen inhibition of Rac1 function.  
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Figure 17: R-Naproxen does not block Rac1 interaction with Tiam1 GEF. (a) 
Controls showing Tiam1 GEF activity effect on Rac1 treated with water and 1 % DMSO. 
(b). Rac1 undergoes normal Tiam1 mediated transition to GDP bound state when treated 
with 100 µM R-Naproxen, 1 µM Tiam1 and 10 µM of phosphatidylinositol 4,5-
bisphosphate lipid. (c) Rac1 undergoes normal Tiam1 mediated transition to GDP bound 
state when treated with 100 µM µM 6-MNA, 1 µM Tiam1 and 10 µM of 
phosphatidylinositol 4,5-bisphosphate lipid. Phosphatidylinositol 4,5-bisphosphate binds 
and activates the lipid homology domain of Tiam1. 
 103 
Molecular docking of R-Naproxen on GDP bound Rac1 predicts possible binding of 
R-Naproxen to the nucleotide binding pocket  
    Molecular docking of R-Naproxen in the nucleotide binding pocket of GDP bound 
Rac1 was prompted by experimental data obtained from cell based assays as well as the 
in vitro Tiam1 GEF assay.  The docking was performed using molecular docking 
OpenEye Fred docking software. The docking results (Fig. 18) predict that GDP bound 
Rac1 state relative to the GTP bound Rac1 is the most favorable orientation which may 
allow R-Naproxen to form H-bonds with Thr17 and Asp57 residues in the nucleotide 
binding pocket. Further examination showed that R-Naproxen may also form hydrogen 
bonds with Mg+2 cofactor in the nucleotide pocket via Naproxen carboxylic group. The 
GTP bound state of Rac1 is missing the nucleotide binding pocket orientation present in 
the GDP bound state which can accommodate R-Naproxen molecule. This suggests that 
R-Naproxen may prefer the GDP bound Rac1 and thus may explain results obtained in 
OVCA433 and Swiss 3T3 cells. 
     Compared to R-Naproxen, the docking of S-Naproxen yielded an unfavorable 
orientation of carboxyl oxygen with respect to favorable interaction with Mg2+ and 
formation of H-bonds with Thr17 and Asp57 amino acid residues. Thr17 residue is 
required for Rac1 activation (240). Taken together, both in vitro and cell based 
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experimental results present R-Naproxen as a small molecule that can functionally inhibit 
Rac1 in ovarian cancer cell lines. Future studies will test the mechanism of action 
predicted by Cheminformatic analysis (Fig. 18). 
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Figure 18: R-Naproxen docks optimally in the nucleotide binding pocket of GDP 
bound Rac1 (a-b) R-Naproxen docked in the nucleotide binding site of Rac1 in the 
(GDP)- bound (PDB code: 1I4D) conformation. Molecular docking carried out using 
Fred docking software. Both GDP and R-Naproxen are shown simultaneously docked in 
the pocket. (c) Interaction map for Rac1-GDP and R-Naproxen showing potential 
hydrogen bonding involving R-Naproxen. 
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Discussion and conclusion 
    Use of cyclooxygenase (Cox) inhibitors to modulate cancer is a field gaining currency. 
Rho GTPases are increasingly being targeted in cancer research due to overwhelming 
evidence suggesting either overexpression or deregulation of some Rho GTPases 
downstream signaling components in a number of human cancers (241, 242). While 
many studies have delineated the downstream effectors of RhoA, Rac1 and Cdc42 as 
responsible for tumor growth and metastasis, direct targeting of these small GTPases with 
small molecules is an area which has not received significant attention. In this study, data 
is presented on the functional characterization of Rac1 using off patent molecules of 
Naproxen and 6-MNA non-steroidal anti-inflammatory drugs (NSAIDs). Rac1 is shown 
to be functionally inhibited by the R-Naproxen isoform in ovarian cancer (OVCA433) 
cells and Swiss 3T3 fibroblast cells at physiologically tolerable concentrations. This is 
characterized by lower levels of activated Rac1 (GTP bound) and redistribution of Rac1 
from the plasma membrane in the presence of R-Naproxen. Functional inhibition of Rac1 
by R-Naproxen is correlated with inhibition of cell-cell adhesion and cell migration in 
ovarian cancer cell lines (Hudson unpublished observations). The functional role of Rac1 
in ovarian cancer cells is similar to reported role of Rac1 in NSCLA SP cells where Rac1 
was found to regulate cell migration, invasion and lung metastasis (212).  
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    Earlier studies have reported that Rho GTPases are involved in the alteration of cell–
cell adhesion status of tumor cells (243). Rho GTPases alter adhesion by coordinating the 
disassembly as well as destabilization of E-cadherin based adhesions (244, 244). Rac1 in 
particular has been shown to promote disassembly of cadherin-dependent adhesion via its 
interaction with PAK1 effector (245). Together, these studies reinforce our findings that 
the inhibition of cell-cell adhesion by R-Naproxen correlates with functional inhibition of 
Rac1. R-Naproxen was shown to alter Tiam1 distribution in the plasma membrane in 
OVCA433 cells even though it did not prevent in vitro Rac1-Tiam1 interaction. The 
observed Tiam1 membrane re-distribution is consistent with loss of OVCA433 cell-cell 
junction and migratory ability. Previous in vitro studies have revealed that Tiam1-
mediated Rac activation is required for proper cell junction formation (246).  This is 
further backed by a study which showed that loss of Tiam1 promotes EMT in vitro and 
the progression of mouse skin tumours in vivo (247, 247). There is also evidence 
suggesting that Tiam1 promotes apical-basal cell polarization in epithelial cells as well as 
promoting directional migration in freely migrating epithelial cells (246, 248, 248). Thus 
R-Naproxen dependent loss of Tiam1 from the membrane of OVCA433 cells may 
contribute to the inhibition of migration and invasion. Like other small GTPases, 
interaction between Rac1 and its regulatory proteins such as Tiam1 occurs via the switch 
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1 and switch 2 regions.  
     In the present study, a possible explanation for the inability of R-Naproxen to inhibit 
Rac1-Tiam1 interaction is that the mode of interaction involving Rac1 and R-Naproxen 
may not involve the Rac1 switch regions. One possible R-Naproxen binding site may be 
the Rac1 nucleotide binding pocket. As a prelude to address the most likely mode of 
action of R-Naproxen, we have employed a cheminformatics approach to show that R-
Naproxen can be docked on the nucleotide binding pocket of GDP bound Rac1 relative to 
that of the GTP bound Rac1. This molecular docking prediction is based on the 
hypothesis that R-Naproxen by binding the nucleotide binding site of Rac1, may stabilize 
Rac1 in the GDP state. 
     R-Naproxen like other NSAIDs is a cyclooxygenase (COX) enzyme inhibitor. 
NSAIDs are known to inhibit the activity of both COX-1 and COX-2, a characteristic that 
accounts for their shared therapeutic and side effects (249). Their ability to inhibit both 
enzymes has to a large extent been attributed to physico–chemical parameter of 
lipophilicity (250). While the inhibition of COX-2 accounts for their common use as anti-
flammatory drugs, inhibition of COX-1 may explain their often unwanted side effects 
such as gastric damage (249, 251). Different processes ranging from inflammation to 
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diseases such as cancer have been linked to COX-2 upregulation (252, 253). In terms of 
drug response, different NSAIDs including R-Naproxen manifest different inhibitory 
potency levels against COX-1 and COX-2 isoenzymes (Appendix F; Glaser et al. Eur J 
Pharmacol, 1995, 281, 107-11; Dannhardt and Kiefer, 2001, Eur J Med Chem, 36, 109-
26). In the data obtained by contracted commercial entity (CEREP, Seattle, USA), R-
Naproxen relative to S-Naproxen, shows lower potency against both COX-1 and COX-2 
enzymes (Appendix F). This further emphasizes the impact of stereoselectivity between 
the two isoforms of Naproxen.  In addition to their known function as COX inhibitors, 
NSAIDs have been shown to have off target effects that may contribute to their in vivo 
effect. Examples include modulation of γ-secretase enzyme, inhibition of the Rho small 
GTPase and its associated kinase Rock, inhibition of translocation of the transcription 
factor NF-κB which activates many genes that promote inflammation, induction of mda-
7/IL-24 expression and inhibition of vascular endothelial growth factor production among 
others (254, 255). All these off target effects are contextually relevant in different disease 
states. 
     In this study, R-Naproxen is shown to be a novel inhibitor of Rac1 activity in 
OVCA333 and Swiss 3T3 cells via COX enzyme independent pathway. This is premised 
on the fact that structurally similar 6-MNA which like Naproxen is a classical COX 
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inhibitor, did not yield statistically significant inhibitory effect on Rac1 activation and 
associated cellular processes in the cell lines considered. More so, there are documented 
studies in different cancer cell lines showing that COX-2 activation occurs downstream 
of Rac1 activation (256, 257). The data shown hear together with other data that are part 
of a comprehensive collaborative study show that R-Naproxen inhibits Rac1 driven 
processes of ovarian cancer cell migration, invasion and proliferation. These are key 
processes that define tumor cell metastasis and therefore the study presents Rac1 as a 
novel therapeutic target in ovarian cancer.  
Implications and significance of R-Naproxen functional inhibition of Rac1  
     There are significant and potential spinoffs of the current study. More importantly, it 
has presented a relatively easy route for Rho GTPase targeting in cancer using small 
molecule. Naproxen is an off patent and cost effective molecule which has survived all 
the rigors of drug development and therefore can be safely used in patients. Secondly, 
since the role of Rac1 in actin remodeling is coordinatively linked to other molecules, 
questions can be posed as to how R-Naproxen (by inhibiting Rac1 activation) may affect 
associated partners such as assembly of the downstream Arp2/3 complex (258, 259), 
nucleating promoting factors (260, 261) and insulin receptor tyrosine kinase substrate p53 
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(IRSp53) (262). These proteins are intimately associated with Rac1 function in actin 
remodeling and associated processes of migration and invasion. Functional inhibition of 
Rac1 also presents an opportunity to target other members of Rho GTPases that together 
with Rac1 define cancer metastasis. There is a need to assess how R-Naproxen isoform 
may functionally modulate Rho (A, B or C) and Cdc42 GTPases in the context of ovarian 
cancer.  
     There is already published evidence on the inhibition of RhoA GTPase associated 
signaling pathway by NSAID, Ibuprofen. The latter was shown to surmount axon growth 
restrictions from myelin and proteoglycans by potently inhibiting downstream pathway 
linked to RhoA (263). The same study also reported that, like Rho and Rock inhibitors, 
Ibuprofen stimulated significant neurite growth in cultured dorsal root ganglion neurons. 
This was confirmed by an independent group which also showed that Ibuprofen reduces 
ligand-induced Rho signaling and myelin-induced inhibition of neurite outgrowth in vitro 
(264). There are also suggestions that ibuprofen and its derivatives may prevent 
Alzheimer's disease by modulating astrocyte reactivity through Rho-GTPase/PAK/ERK-
dependent signaling (265). All these precedents affirm the need to investigate how R-
Naproxen may modulate Rho small GTPase function in cancer models. Preliminary 
findings by Elsa Romero in the Wandinger-Ness laboratory suggest that R-Naproxen also 
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inhibits Cdc42 activation in Swiss 3T3 cells (unpublished) that correlates with disruption 
of Cdc42 membrane localization in OVCA429 cells (Vestling, unpublished). Both 
findings suggest that Rho GTPase may also be a potential R-Naproxen target since Rac1, 
Cdc42 and Rho GTPases are functionally interdependent. 
     It is important to point out that RhoA and Rac1 are involved in the control of the 
levels of matrix metallopro-teinases (MMPs) that degrade the extracellular matrix (ECM) 
in addition to influencing the remodeling of the ECM by regulating tissue inhibitors of 
metalloproteinases (TIMPs)  (245). Degradation of the ECM is a key ingredient in cancer 
cell migration which therefore makes RhoA targeting by R-Naproxen plausible approach. 
It has also been reported that Tiam1 functionally upregulates the transcription of TIMP-1 
and posttranslational levels of TIMP-2 in renal-cell carcinomas (266). This also presents 
an option to investigate if R-Naproxen by causing Tiam1 redistribution from the plasma 
membrane, also affects the levels of TIMP-1 and TIMP-2.  
     Another point for potential extrapolation of the study is in ovarian cancer animal 
models. Establishing Rac1 functional inhibition by R-Naproxen in animal models will not 
only strengthen the current in vitro findings but may also act as a platform for 
translational clinical research applying Naproxen molecule in a cancer context. Taken 
together, this study has shown that Rac1 GTPase and associated cellular processes can be 
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potential targets in ovarian cancer. It has also established that a commonly used NSAID 
Naproxen can be used to target molecular pathways in cancer, a finding which may offer 
potential therapeutic opportunities. In a wider context, this study joins the rank of other 
investigations centered on understanding molecular processes dictating ovarian cancer 
metastasis and how small molecules can be used to modulate them.  
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CHAPTER FOUR 
FUTURE PERSPECTIVES 
Abstract 
    Different strategies can be employed to characterize a small GTPase protein using a 
small molecule. In this dissertation, it has been shown that CID1067700 small molecule 
competitively inhibits nucleotide binding by Rab7 while R-Naproxen allosterically 
inhibits Rac1 function. Both small molecules can potentially be optimized as probes for 
selective targeting of small GTPases. These findings present an important route as far as 
understanding how these important proteins are regulated in diverse cellular processes. 
To date, only few cases about use of small molecules to selectively target small GTPase 
proteins exist much as they dictate the progress of a number of diseases. The best 
examples include small molecule specific inhibition of Golgi trafficking by the fungal 
metabolite brefeldin A and prenylation inhibitors. The latter are however complicated by 
lack specificity since the approach may target a plethora of GTPases. The situation thus 
necessitates the need to explore other small molecules whether allosteric or competitive 
modulators that may be adapted for selective small GTPase targeting. The entire small 
GTPase activation cycle presents diverse points for potential small molecule intervention 
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that may ultimately provide new ideas on mechanism of action. From prenylation 
inhibitors to protein-protein interactions modulators, research on small molecules 
targeting small GTPases may open a new window of opportunity with respect to 
identifying new therapeutic targets in disease states as well as enabling an easier way of 
characterizing protein function. 
Characterized molecular targets and precedents emerging from the current study 
     There have been some limited attempts to find small molecule modulators of small 
GTPase proteins of Rab and Rho sub-families. The small molecules that have been 
characterized to date have centered on modulation of membrane association, nucleotide 
binding or exchange, and inhibition of protein-protein interactions (Fig. 19). The strategy 
of blocking membrane recruitment through inhibition of protein prenylation (267), has 
proven to be effective even though it is limited due to the broad cellular importance of 
lipid modifications for the proper functioning of many GTPase families among other 
proteins. Currently, prenylation inhibitors are primarily geared towards targeting Ras 
GTPases. A major disadvantage of such compounds, however, is the lack of 
specificity/selectivity required for many applications due to overlapping inhibitor activity 
against farnesyl transferases and geranylgeranyl transferases. That notwithstanding, the 
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quest for more specific prenylation inhibitors against the GTPases is aggressively being 
pursued (10, 11, 268, 269, 269, 270). Even if not specific, the prenylation inhibitor results 
suggest that the strategy of delocalizing GTPases from membranes can be effective in 
some cases.  
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Figure 19. Regulation of small GTPases and potential small molecule modulation 
sites. Newly synthesized small GTPases are modified on C-terminal cysteine residues by 
lipid moieties (prenyl or farnesyl chains) to ensure membrane recruitment via REP. GEFs 
and GAPs analogously act as small GTPase signal activators and attenuators, 
respectively. GDI serves to regulate membrane-cytosol cycling. Potential points for 
targeted intervention through small molecules are denoted by brackets. 
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    Another approach for modulating small GTPase function by small molecule is through 
the inhibition of regulatory protein interactions (Fig. 19). Some of the characterized 
examples include the fungal metabolite brefeldin A which has been successfully studied 
as an inhibitor of ADP-ribosylation factor 1 (Arf1) GTPase (271, 272). Brefeldin A 
functions by targeting specific guanine nucleotide exchange factors (GEFs), including 
Golgi complex-specific Brefeldin A resistance factor 1 (GBF1). A stable complex of 
Brefeldin A-GDP-Arf1-GEF on membranes prevents GDP/GTP exchange of Arf1 on 
membrane surfaces and disrupts Golgi morphology (273). Among the Rho-family of 
GTPases, GEF inhibitors such as NSC23766 and its analogs have been identified and 
characterized as allosteric regulators of protein-protein interactions that block Rac1 
interaction with its GEF protein partners (14, 274). In our context, R-Naproxen may also 
modulate Rac1 function in cells via an allosteric mechanism by binding a site distinct 
from the nucleotide binding site. This may be marked by a direct or indirect inhibition of 
Rac1 interaction with its regulatory proteins. Inhibition of Rac1 in this way can be 
significant in situations such as cancer metastasis where blocking of Rac1 dependent cell 
migration is important. While some GEF small molecule inhibitors for the Rho family of 
GTPases have been characterized, none have yet been translated to clinical trials possibly 
due to the immense cost of preclinical studies and drug development of new chemical 
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entities.  Hence the application of an FDA approved molecule could have significant 
advantages.  
    The therapeutic success and selectivity of competitive adenine nucleotide binding 
inhibitors for targeting tyrosine kinases provided the impetus for screens to identify 
guanine nucleotide binding small molecule inhibitors of GTPases (Fig. 19) (135).  
Inhibitors may come in different types. They can either be competitive or non-
competitive inhibitors or just activators of nucleotide binding by the GTPase. As 
discussed above, there are currently few compounds that have been characterized with 
activity against GTPases. EHT1864 is one further example of a small molecule, which is 
demonstrated to inhibit Rac family GTPases albeit in a non-allosteric fashion by placing 
Rac1 in an inert and inactive state (guanine nucleotide displacement mechanism) and in 
the process interfering with Rac1-mediated functions in vivo (223). The screen performed 
as a collaboration between the Wandinger-Ness lab and the UNM Center for Molecular 
Discovery was the first to comprehensively identify both inhibitors and activators for Rho 
and Rab GTPase family members (135). Based on molecular docking prediction, one of 
our running hypotheses in this study is that R-Naproxen may modulate Rac1 function in 
cells in similar way as EHT1864 does by stabilizing Rac1 in the GDP bound state. If this 
holds, it suggests a non-competitive mechanism of inhibition of Rac1 function by R-
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Naproxen and significantly, will lead to inhibition of Rac1 associated downstream 
signaling events that can also be useful against cancer. The caveat will be if the 
specificity of R-Naproxen is sufficient to avoid affecting other GTPases.  
    Prior to the present study, there were no known competitive inhibitors of nucleotide 
binding by small GTPases let alone by the Rab family. Thus, identifying CID1067700 as 
a competitive inhibitor of Rab7 nucleotide binding, not only presents a good platform for 
characterizing GTPase enzymology, but also opens new possibilities for probe 
development that can be extended to other GTPases. One caveat in the use of 
CID1067700 for cell based studies may be its potential to act as a pan inhibitor against 
other GTPases. However, given the SAR data presented in this study and multiplex 
assays performed by Center for Molecular Discovery, chemical modifications show 
promise of selectivity for Rab7 as compared to Rho family GTPases.  This is consistent 
with previous studies from the Wandinger-Ness laboratory that Rab7 showed exquisite 
selectivity by binding BODIPY FL GTP analogues labeled on the 2’ or 3’ oxygen of the 
ribose ring, but not BODIPY FL GTP-γ-NH labeled on the γ-phosphate (133).  RhoA on 
the other hand bound both analogues equally well, indicating nucleotide binding pocket 
differences that affect small molecule binding.   
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    In a physiologic context, small molecule activators or inhibitors of small GTPase are 
expected to be useful in therapeutic applications for various disease states. For instance, 
activators may be useful for diseases where wild-type GTPase expression is reduced or 
there is altered activity. Typical examples include, Niemann-Pick type C disease, 
Huntington’s disease, Charcot-Marie-Tooth disease, and some cancers and ciliopathies.  
On the other hand, inhibitors of guanine nucleotide binding like CID1067700 or allosteric 
inhibitors such as R-Naproxen can be useful for blocking activation in cells, and with 
refinement of specificity may offer great opportunities for modulating individual 
pathways in diseases where overexpression and hyperactivation of GTPases are a 
problem, e.g. cancers, neurodegenerative and infectious diseases. Through the 
mechanistic assessment of small molecules such as CID1067700 and R-Naproxen, both 
an enhanced understanding of the Rab and Rho GTPases with respect to their 
coordination with regulatory proteins, downstream effector proteins and their potential 
for targeted therapies may be gained. 
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APPENDICES 
Appendix A. Rab GTPase functions, networks and disease associations.  Rab 
GTPases are clustered according to their functions in: 1) Endocytosis and recycling; 2) 
Degradation, autophagy, phagocytosis and pinocytosis 
 
Rab  GTPase 
partners 
Localization  Rab Function  Pathological 
condition 
Reference 
 
 
Endocytosis 
and recycling 
     
Rab4a Rab5a, 
Rab11, Rab14 
Early endosomes 
and recycling 
endosomes 
Regulates sorting 
and endocytic 
recycling to the 
plasma 
membrane; 
trafficking of 
human P-
glycoprotein  
responsible for 
multidrug 
resistance of 
tumors; functions 
with Rab14 
through shared 
effector 
RUFY1/Rabip4  
Upregulated in 
rodent model of 
diabetic 
cardiomyopathy, 
human systemic 
lupus 
erythematosus, 
Alzheimer's 
disease and 
Down's 
syndrome; 
inhibited in 
Niemann-Pick 
disease; 
downregulated in 
tumor cells  
(275-282) 
Rab5a Rab4a, 
Rab11, 
Rab15, Rab21 
Plasma membrane, 
clatherin coated 
vesicles and early 
endosomes 
Regulates 
endocytosis,  
early endosome 
fusion, nuclear 
signaling through 
APPL 
Hyperactivated in 
lung 
adenocarcinoma 
due to 
upregulated Rin 
GEF; upregulated 
in Alzheimer's 
Disease 
(276, 277, 
283-287) 
Rab9a Rab7a Late endosomes Implicated in 
transport from 
Endosome to 
trans-Golgi 
network; lipid 
transport; 
lysosome and 
Lysosome related 
organelle 
Inhibited in 
Niemann-Pick C 
disease;  
increased 
function 
beneficial in lipid 
clearance in 
Niemann-Pick 
disease and 
Cystic fibrosis; 
(288-305) 
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biogenesis antagonized by 
pathogens  
Rab11a, Rab11b 
(neuron specific) 
Arf4, Rab8a, 
Rab10, Cdc42 
Golgi and recycling 
endosomes, early 
endosomes,  
phagosomes 
Regulates 
trafficking from 
the trans-Golgi 
network to apical 
recycling 
endosomes and 
plasma 
membrane; 
dopamine 
transporter and 
beta2-adrenergic 
receptor 
trafficking; 
polarized 
trafficking in 
epithelia; 
phagocytosis in 
macrophages 
Upregulated in 
Barrett's 
epithelia; 
neurodegeneratio
n in Huntington's 
disease due to 
inactivation; 
Schwann cell 
demyelination in 
Charcot-Marie-
Tooth type 4C 
disease caused by 
disruption of 
SH3TC2-Rab11 
intreaction; 
Batten disease 
disrupts Hook 
mediated 
interaction of 
CLN3 and Rab11 
(306-319) 
Rab14 Rab4, Rab39 Early endosome, 
Golgi 
Endocytic 
recycling of 
transferrin; MHC 
class I cross-
presentation in 
dendritic cells; 
TGN to apical 
trafficking in 
epithelia; 
surfactant 
secretion in 
alveolar cells; 
insulin-dependent 
GLUT4 
translocation; 
functions 
cooperatively 
with Rab4 
through shared 
effector 
RUFY1/Rabip4; 
regulation of  
embryonic 
development 
through 
interaction with 
Kif16B and 
transport of FGF  
 (281, 282, 
320-327) 
Rab15 Rab5a Early/sorting 
endosome, recycling 
endosome 
Trafficking 
through 
sorting/recycling 
endosomes to the 
plasma membrae; 
attenuates Rab5 
function 
 (328, 329) 
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Rab17  Recycling 
endosome 
Epithelial 
transcytosis; 
polarized 
trafficking in 
kidney 
 (330-332) 
Rab20  Phagosomes, 
mitochondria, 
endosomes 
Vacuolar ATPase 
trafficking in 
kidney; target of 
HIF in hypoxia 
induced 
apoptosis; 
phagosome 
acidification and 
maturation; Gap 
junction 
biogenesis  
Modulated by 
pathogens; 
overexpressed in 
pancreatic and 
breast cancers 
(48, 333-338) 
Rab21 Rab5a Early endosomes; 
macropinosomes 
Endocytosis of 
integrins, cell-
extracellular 
matrix adhesion 
and motility; 
cytokinesis; 
macropinocytosis 
shares  effectors 
and GEFs with 
Rab 5 (APPL, 
Rabex-5 VARP)  
Involved in 
cancer cell 
motility 
(339-348) 
Rab22a Rab5a, Rab7a Early endosome, 
plasma membrane   
Transport of 
transferrin from 
sorting 
endosomes to 
recycling 
endosomes;  
pathogen 
phagocytosis; 
enriched in glia; 
shares effectors 
and GEFs with 
Rab5 (Rabex-5, 
EEA1) 
Upregulated in 
hepatocellular 
carcinoma;  
mycobacterium 
tuberculosis 
inhibits 
phagosome 
maturation by 
blocking Rab22a 
to Rab7 transition 
required for late 
endosome fusion 
and 
phagolysosome 
formation  
(340, 349-
356) 
Rab25 Rab11a Recycling 
endosome 
Apical recycling 
in epithelia,  
microtubule 
dependent 
transformation 
Tumor 
progression and 
cancer 
invasiveness 
(down regulated 
in breast and 
intestinal cancers; 
upregulated in 
ovarian cancer 
and 
hepatocellular 
carcinoma) 
(306, 347, 
351, 357-370) 
Rab31/ Rab22b  Trans Golgi 
network (TGN) and 
Mannose 6-
phosphate 
transport from 
 (371) 
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endosomes TGN to 
endosomes; 
enriched in glia; 
transport of 
proteins involved 
in myelination 
from TGN to 
plasma 
membrane via 
endosomes 
Rab34 Rab7a, Rab36 Golgi and 
endosomes 
Endosomes, 
macropinosome 
formation, 
phagosome 
maturation, 
lysosome 
morphogenesis, 
functions with 
Rab36 and Rab7 
through shared 
effector (RILP) 
Diabetic 
nephropathy 
(48, 372-379) 
Rab35 Cdc42 Endosomes and 
plasma membrane 
Fast endocytic 
recycling; MHC 
class I and II 
endocytosis and 
recycling; Tcell 
recpetor 
recycling; 
phosphoinositide 
regulation; 
neurite outgrowth 
through interfaces 
with Cdc42; actin 
remodeling 
through fascin 
effector leading 
to filopodia 
formation 
Pathogen 
phagocytosis and 
trafficking 
(380-388) 
Rab36 Rab7a, Rab34 Golgi Late endosome 
and lysosome 
clustering; 
functions with 
Rab7 and Rab34 
through shared 
effector RILP 
Potential function 
as tumor 
suppressor 
(372, 389, 
390) 
Rab39 Rab14 Golgi and early 
endosomes, AP1 
membrane domains 
Caspase-
dependent-IL-
1beta secretion; 
homology to 
Rab14; 
phagosomal 
acidification  
 (48, 325, 391, 
392) 
Autophagy, 
Phagocytosis 
and Degradation 
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Rab7a Rab5a, 
Rab9a, 
Rab34, Arf6, 
Rac1 
Late endosomes and 
lysosomes; stage I 
and II 
melanosomes; 
surfactant 
endocytosis and 
signaling 
Transport from 
early to late 
endosomes and 
late endosome to 
lysosome fusion; 
bidirectional 
transport of 
signaling 
endosomes, 
autophagosomes, 
multivesicular 
bodies, and 
melanosomes on 
microtubules in 
association with 
dynein and 
kinesin motor 
proteins; axon 
viability; 
phosphoinositide 
homeostasis; lipid 
transport; 
activation of 
mTOR signaling; 
lung innate and 
adaptive 
immunity based 
on upregulation 
in alveolar 
macrophages by 
surfactant SP-A   
Mutant in 
Charcot-Marie-
Tooth Disease 
Type 2B 
(CMT2B); 
modified to 
promote 
intracellular 
pathogen 
survival; 
increased 
function 
beneficial in lipid 
clearance in 
Niemann Pick 
disease; 
upregulated in 
Alzheimer's 
Disease, thyroid 
cancer, diffuse 
peritoneal 
malignant 
mesothelioma, 
adult-onset 
obesity; mutation 
of downstream 
effector Vps33b 
causal  in 
arthrogryposis-
renal-cholestasis 
(21, 27, 30, 
32-34, 37, 38, 
49, 51, 61, 63, 
69, 71, 117, 
122, 125, 287, 
365, 393-398) 
Rab24  Autophagosomes, 
nuclear inclusions 
Myelination; 
autophagosome 
formation 
Activated in cell 
culture models of 
neuronal  and 
cardiomyocyte 
injury leading to 
the increased 
autophagy; 
upregulated in 
hepatocellular 
carcinoma  
(351, 355, 
399-403) 
Rab32  Perinuclear vesicles, 
mitochondria, 
autophagic vesicles 
Post-Golgi 
trafficking of 
melanogenic 
enzymes; ER 
stress mediated 
apoptosis; 
mitochondrial 
dynamics 
Rab32 gene 
methylated in 
inflammatory 
bowel disease at 
transition to 
invasive growth 
(346, 404-
408) 
Rab33  Golgi, 
autophagosomes 
Autophagosome 
formation; 
interacts with 
Atg16L 
 (409, 410) 
Rab43  Phagosome Cathepsin D 
transport to 
phagosomes 
 (48) 
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APPENDIX B.  Rab GTPase effector regulators and associated cellular functions  
 
Rab Rab Effector Effector function References 
Rab4a-GTP Rabaptin-4 Assists in the docking of transport 
vesicles en route from early 
endosomes to recycling 
endosomes  
(411) 
 Rabaptin-5 Activates Rab5 through complex 
with Rabex-5 and links Rab5 with 
Rab4 
(412, 413) 
 Rabip4 Regulates transport through early 
endosomes 
(414) 
Rab5a-GTP EEA1 Coordinates tethering and fusion (415-417) 
 p110beta/p85 PI 
3-kinase 
Ensures coupling of the lipid 
kinase product to its downstream 
target, protein kinase B. 
(418) 
 Phosphoinositide 
3-kinase 
(hVps34/hVps15) 
Regulates SNARE complex 
formation or disassembly 
(419) 
 Rabaptin-5 Activates Rab5 through a  
complex with Rabex-5, Links 
Rab5 with Rab4, and facilitates 
membrane docking and fusion.  
(412, 420, 421) 
 Rabaptin-5beta Stabilizes Rabex-5 recruitment 
and facilitates membrane fusion 
in concert with Rabaptin-5 
(421, 422) 
 Rabenosyn-5 Required for CCV-EE and EE-EE 
fusion, regulates the functional 
link between Rab5 and Rab4 
domains 
 (423, 424) 
  Rabip4 Regulates transport through early 
endosomes 
(414) 
Rab5a-GDP Rabex-5 GEF for Rab5 (421, 425, 426) 
 RIN1 GEF for Rab5 and activated by 
growth factor signaling 
(427) 
 RIN2 May function as upstream 
activator and downstream effector  
(428) 
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Rab7a-GTP ANKFY1 Possible role in vesicular 
trafficking. Novel interactor of 
Rab7. Specific role yet to be 
established 
(125, 429) 
 Armus/Rac1 Regulates cytoskeleton 
organization, ruffled border 
formation in osteoclasts, 
inactivates Rab7 and regulates E-
cadherin degradation. 
(21, 303) 
 ATP6V0A1 Component of vacuolar ATPase 
that regulates organelle 
acidification required for protein 
sorting, receptor mediated 
endocytosis, zymogen activation 
and synaptic vesicle proton 
gradient. Novel interactor of 
Rab7. Specific role yet to be 
established 
(125, 430) 
 FYCO1 (FYVE 
and coiled-coil 
domain 
containing 1) 
Implicated in microtubule plus 
end transport of autophagosomes 
presumably through interaction 
with kinesin.  
(41) 
 GNB2L1 Role in intracellular signaling and 
activation of protein kinase C and 
possible interaction with Rab7 via 
WD40 domain. Novel interactor 
of Rab7. Specific role yet to be 
established 
(125) 
 HOPS complex 
(Vps11,-16,-18,-
33,-39 and-41)  
Involved in endo-lysosomal 
transport. Vps39 binds Mon1-
Ccz1 complex that serves as a 
Rab7 GEF in yeast. 
(115, 431, 432) 
 hVps39  In yeast, cooperates with Mon1-
Ccz1 complex to promote Rab7 
nucleotide exchange. 
(141, 431) 
 IMMT (Mitofilin) Maintains mitochondrial 
morphology and suggested role in 
protein import. Novel interactor 
of Rab7. Specific role yet to be 
established. 
(125) 
 KIF3A (kinesin + 
adapter?) 
Associates with late endosomes 
along with dynein, Rab7 and 
dynactin. Possible mediator of 
Rab7 regulated anterograde 
transport. 
(70) 
 Mon1a-Mon1b Mammalian homologs of C. 
elegans SAND1. Mon1a-Mon1b 
causes Rab5 GEF displacement 
and Mon1b interacts with the 
HOPS complex. HPS1 
(116, 433-435) 
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 ORP1L Required for activation of dynein/ 
dynactin motor, regulates late 
endosome/lysosome 
morphogenesis and transport. 
(78)  
 Phosphoinositide 
3-kinase 
(hVps34/hVps15) 
Regulates activity of Vps34 and 
generates PI3P to control 
endosomal trafficking and 
signaling. 
(18) 
 Plekhm1 
[pleckstrin 
homology 
domain 
containing, 
family M (with 
RUN domain) 
member] 
Regulates vesicular transport in 
osteoclasts. 
(304) 
 Prohibitin Negative regulator of cell 
proliferation and a possible tumor 
suppressor. Novel interactor of 
Rab7, specific role yet to be 
established. 
(125) 
 Rabring7 Rab7 interacting RING finger 
protein, functions as E3 ligase 
that ubiquitinates itself and 
controls EGFR degradation. 
(85) 
 Retromer (Vps26, 
Vps29, Vps35) 
Regulates retrograde transport 
from late endosome to trans-Golgi 
network (TGN) through direct 
interaction with Vps26. 
(436) 
 RILP (Rab7 
interacting 
lysosomal 
protein) 
Involved in late 
endosomal/lysosomal maturation. 
Recruits dynein-dynactin motor 
protein complex. 
(69) 
 Rubicon Regulates endosome maturation 
through differential interaction 
with UVRAG and Rab7. 
(437) 
 Spg21 Involved in vesicular transport. 
Novel interactor of Rab7. Specific 
role yet to be established. 
(125, 438)    
 Stomatin like 2 
(STOML2) 
Negatively modulates 
mitochondrial sodium calcium 
exchange. Novel interactor of 
Rab7. Specific role yet to be 
established. 
(125) 
 TrkA  Interacts with Rab7 and regulates 
endocytic trafficking and 
signaling as well as influencing 
neurite outgrowth. 
(33, 439) 
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 UVRAG/Beclin1 UVRAG/C-Vps complex 
regulates Rab7 activity during 
autophagic and endocytic 
maturation.  
(38) 
 VapB Involved in vesicular trafficking 
and novel interactor of Rab7. 
Specific role yet to be established. 
(125) 
 Vps13c Vacuolar protein sorting and 
novel interactor of Rab7. Specific 
role yet to be established. 
(125) 
Rab7a-GTP, 
GDP 
Ccz1 Recruited to endosomes by 
Mon1a/Mon1b and acts as Rab7 
GEF in yeast. Possible human 
homolog C7orf28B also some 
similarity to HPS4 involved in 
biogenesis of lysosome related 
organelles. 
(116, 433-435) 
 TBC1D5 Negatively regulates retromer 
recruitment and causes Rab7 to 
dissociate from membrane. 
(110) 
 TBC1D15 Functions as Rab7 GAP. Reduces 
its interaction with RILP, 
fragments lysosomes and confers 
resistance to growth factor 
withdrawal induced cell death. 
(109, 142)                                                    
 XAPC7/PSMA7 
alpha proteasome 
subunit 
 Negative regulator of late 
endocytic transport. 
Overexpression inhibits EGFR 
degradation.  
(71) 
Rab7b SP-A (Surfactant 
Protein A) 
Transiently enhances the 
expression of Rab7 and Rab7b 
and makes them functionally 
active to increase the 
endolysosomal trafficking in 
alveolar macrophages. 
(398) 
Rab8a-GTP Cpn 0585 Facilitates Rab8 recruitment to 
Cpn inclusion membrane 
(440) 
 FIP-2 May be implicated in 
morphogenesis 
(441) 
 TRIP8b Regulates secretory pathway (442) 
  MAP4K2 
(Rab8IP) 
Rab-regulated protein 
phosphorylation, secretion 
pathway 
(286, 443) 
 Ahi Ciliogenesis (444) 
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 BBSome Ciliogenesis; cilial transport (445) 
 Cenexin3 (OFD2 
splice variant) 
Binds microtubules and basal 
bodies, ciliary biogenesis 
(446) 
 Ellipsa (via 
Rabaptin5) 
Intraflagellar transport (447) 
 FIP-2 Recruitment of Huntingtin to 
Rab8-positive vesicular 
structures; Polarization 
(441) 
 GDI-2 GDI (448) 
 GLUT4 Glucose transport (449) 
 JRAB/MICAL-
L2 
Adherens junction and tight 
junction assembly 
(450) 
 MICAL-L1 EHD1-Rab8a interaction, 
membrane tuble localization 
(451) 
 MSS4 Weak GEF or chaparone (452, 453) 
 Myosin Vb Motor - Insulin-induced GLUT4 
translocation 
(321) 
 Noc2 Effector (454) 
 OCRL1 Phosphatase (455, 456) 
 Optineurin/FIP2 Post-Golgi trafficking/exocytosis (457) 
 Otoferlin Trans-Golgi trafficking (458) 
 Rabaptin-5 Molecular bridge for intraflagella 
transport 
(447) 
 RIM2 Scaffold  (454) 
 Sro7(Sec4p- 
Yeast 
homologue) 
Potential SNARE regulation (459) 
 XM_037557 GAP (446) 
Rab8a-GDP Rabin8 GEF (460) 
 Rabin3(rat) GEF (460) 
Rab8b TRIP8b Secretory pathway regulation (442) 
Rab9a-GTP P40 Mediates late-endosome-to-TGN 
vesicular transport 
(461) 
 TIP47 Facilitates MPRs  transport (291) 
 GCC185 Involved in MPRs recycling (462) 
 INPP5B Could be facilitating secretory (463) 
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pathway 
Rab10 Cpn 0585 Facilitates Rab10 recruitment to 
Cpn inclusion membrane 
(440) 
 EVI5 Potential GAP (456, 464) 
 Exocyst Cilial trafficking (465) 
 GDI-1 GDI  (466) 
 MSS4 Chaparone (452) 
 Myosin 
Va,Vb,Vc 
Motor (467) 
 Rim1 Scaffold (454) 
 TBC1D4 GAP (22) 
Rab11a-GTP RIP11 Regulates multiple distinct 
membrane trafficking events 
(468) 
 RCP Regulates protein sorting in 
tubular endosomes 
(469) 
 FIP5/RIP11 Endocytic recycling; exocytosis (470) 
 Evi5 GAP (471) 
 FIP3/Arfophilin/
Eferin 
Mediate transport to the 
endosomal-recycling 
compartment, endocytic 
regulation, abscission 
 (472) 
 Rab11BP/Rabphil
in 11 
Vesicle recycling (286, 473) 
 Sec15 Exocyst component, endocytic 
recycling 
(474) 
 FIP1 Recycling (475) 
 FIP4 Recycling, Regulation of retinal 
development, abscission 
(476) 
 FIP2 Recycling (477) 
 Presenilin 1    Trafficking chaparone (478) 
 Presenilin 2 Trafficking chaparone (478) 
 PI4-kinase β Localization of rab11 to the Golgi 
complex, post-Golgi trafficking 
(479) 
 Myosin Va   Motor (476, 480) 
 Myosin Vb,  Motor (481) 
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 D-AKAP2 Endosome morphology and 
protein accumulation 
(482) 
 D. melanogaster 
nuclear fallout 
(Nuf)  
Recycling endosomes, Cleavage 
furrow membrane integrity, actin 
remodeling   
(64) 
 Rab6 interacting 
protein 1 
Rab6-Rab11 interaction (483) 
 SH3TC2 Recycling endosome (317) 
 Syntaxin 4A    t-SNARE, regulatator of secretion (484) 
 Sec15 Exocyst component, endocytic 
recycling 
(474) 
Rab11a-GDP GDP dissociation 
inhibitor 2   
GDI (448) 
Rab11b-GTP 
(neuron 
specific) 
myosin vb Cargo recycling (485)  
 Rabphilin-11 Vesicle recycling (473) 
 Rab6 interacting 
protein 
Links Rab6 and Rab11 (483) 
 Cpn 0585 Facilitates Rab11b recruitment to 
Cpn inclusion membrane 
(440) 
 Evi5 Coordination of vesicular 
trafficking, cytokinesis, and cell 
cycle regulation 
(319, 471) 
Rab15 Rab15 effector 
protein 
Regulates receptor recycling from 
the recycling compartment  
(328) 
 Cpn 0585 Facilitates Rab15 recruitment to 
Cpn inclusion membrane 
(440) 
 FIP1 Recycling (475) 
 FIP2 Recycling (475) 
 FIP3 Recycling (475) 
 Myosin Vb Motor (486) 
 RIP11 Insulin granule exocytosis (487) 
Rab17 TBC1D7 GAP (22, 446) 
Rab21 alpha-integrin 
subunit 
Regulates vesicular motility of 
integrins 
(344)  
 Varp GEF for Rab21 (488) 
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Rab22a EEA1 May be linking Rab22a with early 
endocytic pathways 
(352)  
 Rabex-5 Links Rab22-Rab5 signaling 
cascade 
(356) 
 Rabenosyn-5 May be involved in endosomal  
tethering 
(489) 
Rab23 EVI5-like GAP  (22, 446) 
Rab25 Integrin beta-1 
subunit 
Promotes cell migration (359) 
Rab27a Exophilin4 Mediates the peripheral 
localization of melanosome and 
glucagon granules 
(490-492) 
Rab27a/b Melanophilin Mediates the peripheral 
localization of melanosome and 
glucagon granules  
(493-496) 
Rab27a-GDP Granuphilin Regulates dense-core vesicle 
exocytosis 
(497) 
Rab27a/b Rabphilin Modulates secretory vesicle 
exocytosis 
(498) 
Rab27a/b Noc2 Modulates dense-core vesicle 
exocytosis 
(498, 499) 
Rab27a/b Munc13-4 Modulates dense-granule 
secretion from platelets 
(500) 
Rab27a/b Slp2a Regulates melanosome transport (490) 
Rab32 Varp  Regulates Tyrp1 trafficking in 
Melanocytes 
(339, 346)  
 PKA Regulates melanosome transport (501) 
Rab33a ATG16L Regulates autophagosome 
formation involving Rab33a 
(409) 
 GM130 May be involved in the docking 
and fusion of vesicles in the Golgi 
apparatus 
(502)  
 Rabaptin-5 May be involved in the docking 
and fusion of vesicles in the Golgi 
apparatus 
(502)  
Rab33b ATG16L Regulates autophagosome 
formation involving Rab33b 
(410) 
 Rabex-5 May be involved in the docking 
and fusion of vesicles in the Golgi 
apparatus 
(502) 
Rab34 RILP Regulate lysosome (379) 
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morphogenesis 
 Hmunc13 Mediates lysosome-Golgi 
trafficking 
(375) 
Rab35 Fascin May stimulate actin bundling (388) 
Rab36 RILP Regulates spatial distribution of 
late endosomes and lysosomes 
(372) 
 GAPCenA   Acts as a GAP (503) 
Rab38 Varp  Regulates Tyrp1 Trafficking in 
Melanocytes 
(346, 504) 
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APPENDIX C: Conformational state of Rab7 when bound to Rab7: Interaction 
between CID1067700 and Rab7 does not cause transition of Rab7 to GTP conformation. 
GST-RILP is mobilized on glutathione beads and then interaction between RILP and His-
SUMO-GFP-Rab7 with Rab7 in the GTP bound state is measured using flow cytometry.  
Incubation with either CID1067700 or GDP precludes interaction. Fluorescence output 
from GFP is a measure of Rab7 binding. 
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APPENDIX D.  Rho GTPase (1). Key functions, (2). Some of the characterized GEFs 
and GAPs, and (3). Association with cancer  
 
Rho 
GTPase 
protein 
Key function Characterized 
GEF 
Characterized 
GAP 
Cancer link Reference 
Cdc42 Regulates 
formation of and 
filopodia, 
maintenance of 
cadherin-mediated 
cell-cell adhesion 
Dbs; 
Intersectin,Tuba, 
CopE, Fgd1, 
Vav1/2/3, 
Ephexin, Asef, 
DOCK2/9 
p50rhoGAP 
(GMPPNP), n-
Chimaerin 
Breast, 
melanoma, 
squamous-cell 
carcinoma 
(SCC), 
colorectal, 
testicular 
(180, 505-514) 
Rac1a Regulates cell 
membrane 
ruffling, formation 
of lamellipodia, 
maintenance of 
cadherin-mediated 
cell-cell adhesion 
Tiam1, Vav1/2/3, 
Ephexin, Trio, 
Sos1/2, Asef, 
Dock4 
β2-chimaerin, n-
Chimaerin, 
ArhGAP15 
Breast, 
melanoma, SCC, 
colorectal, lung, 
testicular, 
gastric, renal 
(180, 193, 507, 
511, 511-518). 
Rac1b Suspected to 
promote cellular 
transformation 
    Colon, breast  (207, 512, 519) 
Rac2 Regulation of 
NADPH oxidase 
activity,  
DOCK2/9, P-Rex1   Head and neck 
squamous-cell 
carcinoma, 
chronic 
myelogenous 
leukemia 
(520-524) 
Rac3 Regulates cell 
invasion  
    Non-IBC (512, 525) 
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RhoA Regulates 
formation of actin 
stress fibers and 
focal adhesions, 
Implicated in 
thrombin-, serum-, 
and LPA-induced 
neurite retraction 
and cell rounding, 
maintenance of 
cadherin-mediated 
cell-cell adhesion, 
regulates 
cytokinesis 
XPLN, Vav1/2/3, 
Ephexin, Syx, 
p63RhoGEF, 
Tech, Arhgef5,  
ARAP3, 
MgcRacGAP 
Colon, breast, 
lung, testicular 
germ cell, head 
and neck 
squamous-cell 
carcinoma; 
melanoma, 
colorectal, 
pancreas, lung, 
testicular, 
ovarian, gastric, 
liver, pelvic 
ureteric, 
prostrate, 
neuroblastona, 
bladder, 
leukemias AML, 
sarcoma, 
hepatocellular 
carcinoma 
(180, 511, 512, 
520, 526-540) 
RhoB Mediates 
apoptosis 
XPLN   Breast, lung and 
HNSCCa  
(537, 541-546)  
RhoC Modulates 
induction of 
angiogenic 
factors  
 SmgGDS   Inflammatory 
breast cancer, 
pancreatic ductal 
adenocarcinoma; 
breast IBC; non-
IBC; melanoma; 
SCC; pancreas; 
lung; non-small 
cell lung cancer; 
ovarian, gastric; 
bladder; 
Hodgkin's, 
hepatocellular 
carcinoma, 
prostrate 
(512, 539, 547-
550, 550-554)  
RhoD Regulates cell 
migration and 
cytokinesis,  
       (555, 556) 
RhoE/Rnd3 Cytoskeletal 
organization and 
cell cycle 
progression, 
regulates activity 
of RhoA 
    Non-small cell 
lung carcinoma 
 (557, 558) 
RhoG Regulates 
endothelial apical 
cup assembly, 
regulates the 
neutrophil 
NADPH oxidase, 
regulates gene 
expression and the 
Trio   Non-IBC (512, 559, 560) 
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actin cytoskeleton 
in lymphocytes 
RhoH Acts as an adaptor 
molecule in TCR 
signaling pathway 
    Non-Hodgkin’s 
lymphoma, 
multiple 
myeloma 
 Diffuse large B-
cell lymphomas 
(512, 561, 562) 
Rnd1/2/3 Regulates axon 
guidance and 
neurite extension, 
regulates 
formation of stress 
fibers 
    Non-IBC (512, 557, 563) 
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Appendix E. Comparative functional effect of other NSAIDs on Rac1: i) Aspirin; ii) 
Ibuprofen; iii) Fenoprofen; iv) Ketoprofen, do not show significant effect on membrane 
localization of Rac1 GTPase in OVCA433 cells at similar concentration of treatment and 
duration as R-Naproxen.   
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Appedix E (i): Relative to control (0.2 % DMSO), 300 µM of Aspirin does not cause 
significant membrane redistribution of Rac1 in OVCA433 cells after 1hr of treatment. 
This is unlike the case of R-Naproxen at the same concentration and duration of 
treatment.  
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Appedix E (ii): Relative to control (0.2 % DMSO) and also compared to R-Naproxen, 
300 µM of Ibuprofen does not cause significant membrane redistribution of Rac1 in 
OVCA433 cells after 1 h of treatment.  
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Appedix E (iii): Relative to control (0.2 % DMSO), 300 µM of Fenoprofen does not 
cause significant membrane redistribution of Rac1 to the cytosol in OVCA433 cells after 
1 h of treatment unlike R-Naproxen at the same concentration and duration of treatment.  
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Appedix E (iv): Relative to control (0.2 % DMSO), 300 µM of Ketoprofen does not 
cause significant membrane redistribution of Rac1 in OVCA433 cells after 1 h of 
treatment. Rac1 is still significantly present at the plasma membrane unlike the case of R-
Naproxen at the same concentration and duration of treatment.  
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Appendix	  F:	  COX enzyme inhibitory activity of a panel of NSAIDs 
 
COX-1 IC50 (M)  
Compound  nH 
1-6MNA 2.80E-05 1 
2-R-Nap 7.20E-06 0.6 
3-S-Nap 5.90E-08 0.9 
Pub Chem: CID2950007 1.80E-06 0.9 
5-R-Keto 9.90E-07 0.9 
6-S-Keto <1.0E-0.8 NA 
   
COX-2   
Compound   
1-6MNA >1.0E-04 NA 
2-R-Nap 4.20E-06 0.9 
3-S-Nap 7.00E-08 1.3 
Pub Chem: CID2950007 5.80E-07 0.8 
5-R-Keto >1.0E-04 NA 
6-S-Keto 8.5E-0.8 1.4 
 
6-MNA: 6-Methoxy-2-naphthalene acetic acid 
Assay performed through a contract agreement with CEREP, Seattle, U.S.A.	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